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When cardiac
complaints occur
in the absence
of organic findings,
underlying
anxiety may be
one factor
The influence of anxiety on heart function
Excessive anxiety is one of a combina,
tion of factors that may trigger a series of
maladaptive functional reactions which can
generate further anxiety. Often involved in
this vicious circle are some cardiac arrhyth,
mias, paroxysmal supraventricular tachycar,
dia and premature systoles. When these
symptoms resemble those associated with
actual organic disease, the overanxious
patient needs reassurance that they have no
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organic basis and that reduction of exces,
sive anxiety and emotional overreaction
would be medically beneficial.
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sistency. Because of its wide margin of safety,
Librium may generally be administered for ex,
tended periods, at the physician's discretion1
without diminution of effect or need for increase
in dosage. If cardiovascular drugs are necessary,
Librium 1s used concomitantly whenever anxiety
is a clinically significant factor. Librium should
be discontinued when anxiety has been reduced
to appropriate levels.
in presence of impaired renal or hepatic function. Paradoxical reactions
(e.g., excitement, stimulation and acute rage) have been reported in psychiatric patients and hyperactive aggressive children. Employ usual precautions
in treatment of anxiety states with evidence of impending depression; suicidal
tendencies may be present and protective measures necessary. Variable effects
on blood coagulation have been reported very rarely in patients receiving the
drug and oral anticoagulants; causal relationship has not been established
clinically.
Adverse Reactions: Drowsiness, ataxia and confusion may occur, especially in the elderly and debilitated. These are reversible in most instances by
proper dosage adjustment, but are also occasionally observed at the lower
dosage ranges. In a few instances syncope has been reported. Also encountered
are isolated instances of skin eruptions, edema, minor menstrual irregularities,
nausea and constipation, extrapyramidal symptoms, increased and decreased
libido- all infrequent and generally controlled with dosage reduction; changes
in EEG patterns (low-voltage fast activity) may appear during and after treatment; blood dyscrasias (including agranulocytosis), jaundice and hepatic dysfunction have been reported occasionally, making periodic blood counts and
liver function tests advisable during protracted therapy.
Supplied: Librium® Capsules containing 5 mg, 10 mg or 25 mg chlordiazepoxide HCI. Libritabs® Tablets containing 5 mg, 10 mg or 25 mg
chlordiazepoxide.

For relief of
excessive anxiety
adjunctive

Libriunr
tOmg
(chlordiazepoxide HCl)
1or2 capsules t.i.d./q.i.d.

®

Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, N.J. 07110

MCV/Q
MEDICAL COLLEGE OF VIRGINIA QUARTERLY
A Scientific Publication of the School of Medicine
Health Sciences Division of Virginia Commonwealth University

1974 • Volume Ten • Number Four
MEDICAL COLLEGE OF VIRGINIA
QUARTERLY Published quarterly
(Spring, Summer, Fall, Winter), by the
Medical College of Virginia, Division of
Health Sciences, Virginia Commonwealth
University. The QUARTERLY publishes
results of original research in basic and
clinical sciences. Contributions from outside the Medical College of Virginia faculty are invited. Manuscripts, submitted in
duplicate, should be prepared according
to recommendations in the Style Manual
for Biological Journals, Washington,
D.C., American Institute of Biological
Sciences, Second Edition, 1964.
Correspondence: MEDICAL COLLEGE
OF VIRGINIA QUARTERLY, Medical
College of Virginia, Richmond, Virginia
23298. Phone 804/ 770-4027.
Subscription rates for U.S.A., Canada,
and Mexico: 1 year, $6.00; 2 years, $10.00;
3 years, $14.00. All other countries: 1
year, $8.00; 2 years, $12.00; 3 years,
$15.00. Libraries and institutions:
(U.S.A.) I year, $12.00; 2 years, $20.00; 3
years, $28.00; <foreign) I year, $13.00; 2
years, $21.00; 3 years, $29 .00. Interns,
residents, and students: 1 year, $3.00.
Single issue: $2.00.
Third class postage paid at Richmond,
Virginia.

Editorial Advisory Board
John T. Farrar
Ernst G. Huf
Hunter H. McGuire
M. Pinson Neal, Jr.
Kinloch Nelson
Frederick J . Spencer
Editorial Consultants
Larry F. Cavazos Boston
Richard G . Lester Durham
Sarni I. Said Dallas
Malcolm E. Turner, Jr. Birmingham
Editor
Fairfield Goodale, Jr.
Managing Editor
Catherine C. Elverston
Editorial Assistant
Alice C. Reier
Cover Design
Raymond A. Geary

164

CONTENTS

Clinical Advances in Medical and Surgical Neurology-Part II
Sponsored by the Department of Continuing Education and the Division of Neurosurgery, Medical College of Virginia, Health Sciences
Division of Virginia Commonwealth University.
DONALD

P. BECKE R, M.D., Guest Editor

Introduction
DONALD

166

P. BECKER, M.D.

Clinical Advances in the Management of Patients
with Severe Head Injury

167

THOMAS W. LANGFITT, M . D.

Continuous Intracranial Pressure Monitoring
with Brain Injury: Technique and Application

m

Patients
174

JOHN K. VRIES, M.D .

Neuro-Ophthalmology in Severe Head Injury

178

JOHN W. HARBISO N, M.D.

Advances in Neuroradiology

183

FREDERICKS. VINES, M.D .

Advances in the Management of Pituitary Tumors

192

CHARLES B. WILSON, M.D.

Advances in the Treatment of Patients with Benign Brain Tumors

196

HAROLD F. YOUNG, M.D.

Advances in the Management of Patients with
Malignant Brain Tumors
CHARLES B . WILSON, M.D.

200

Practical Anticonvulsant Pharmacokinetics

205

R . B. DAVID, M.D.
L. K. GARRETTSON, M . D.

Advances in the Medical and Surgical Management of
Intractable Partial Complex Seizures

208

HOOSHANG HOOSHMAND, M . D.

Radical Reconstruction of Complex Cranio-OrbitoFacial-Abnormalities

220

JOHN A. JANE, M.D . , PH.D.
MILTON

T.

EDGERTON, M . D .

Progress and Problems in the Rehabilitation of Patients
with Central Nervous System Injuries
224
L. D. AMICK, M.D.

COVER: "Scene of a trepanation performed by Andre de la
Croce." Engraving used as part of design for Part I and II is from
Horrax, Gilbert, Neurosurgery: An Historical Sketch, First Edition,
1952. Courtesy Charles C. Thomas, Publisher, Springfield, lllinois.
©

1974 by the Medical College of Virginia, Health Sciences Division of Virginia Commonwealth
University
Printed by the William Byrd Press, Richmond, Virginia

INTRODUCTION
This issue represents the second part of the 27th
Annual Stoneburner Lecture Series delivered at the
Medical College of Virginia in February 1974. The
first part emphasized basic and clinical aspects of
cerebral vascular disease and basic mechanisms in
brain injury and was published in the preceding issue
of the MCV/ Q.
Here, we are dealing with clinical applications of
recent advances in our understanding of brain mechanisms and brain disease processes. The Stoneburner
Lecturer was Dr. Thomas W. Langfitt, the Charles H.
Frazier Professor and Chairman of the Division of
Neurosurgery at the University of Pennsylvania.

DONALD P. BECKER, M.D.

Professor and Chairman
Division of Neurosurgery
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Clinical Advances 1n the Management of
Patients with Severe Head Injury*
THOMAS W. LANGFITT, M.D.

Charles H. Frazier Professor and Chairman, Division of Neurosurgery,
University of Pennsylvania, Philadelphia

Some of the physiological properties of the
cerebral circulation, intracranial pressure and brain
metabolism, as well as some of the pathophysiological alterations that we see with various
types of brain injuries have been discussed in this series. We are going to see how we can apply some of
this information clinically. I will begin with a patient.
A patient, comatose following a severe head irijury, is brought into the emergency room. Our
method of managing these patients has evolved over
a number of years. Although I shall present the
procedure to you sequentially, in fact, much is done
virtually simultaneously. As always, the first thing
that one must attend to is the airway. The majority of
comatose head-injured patients, upon admission to
the emergency ward, have a hyperventilation syndrome. It is of primary necessity, in this situation, to
obtain an arterial blood sample for measurement of
Pa 0 , Paco, and pH. Frequently, the patient is
hypocapni~, with a Paco, of perhaps 30, and is hypoxic as well. In a large series from several clinical units,
the average Pa 0 , of several hundred patients at the
time of admission was about 65-70 mm Hgsomewhat hypoxic but generally not severely so.
How can the patient be hyperventilating, be
hypocapnic, and hypoxic at the same time? Nearly all
of these patients have some degree of pulmonary
aiteriovenous shunting but are able to eliminate the
C0 2 with their relatively inadequate respirations,
because C0 2 diffuses across the alveolar membrane at
• This is an edited transcription of a lecture presented by Dr.
Langfitt at the 27th Annual Stoneburner Lecture Series, February
8, 1974, at the Medical College of Virginia, Richmond.
MCV QUARTERLY 10(4): 167-173, 1974

twenty times the rate of oxygen. At the same time,
they are not able to get enough 0 2 into the blood.
Hypoxia and hypocapnia are a very common
pulmonary syndrome in these patients.
if the patient looks as though he is severely brain
injured and is not going to recover soon, we go straight
to intubation after drawing the arterial blood gas.
The patient's airway is cleaned and he is then ventilated with an Ambu® bag. By now, someone is taking
the blood pressure and the heart rate. If the patient
has a mass lesion, then, in a majority of cases, he has
a so-called Cushing response consisting of arterial
hypertension. He may or may not have bradycardia;
in fact, in our experience, in the acute brain injured
patient; tachycardia is more common than bradycardia, except in those patients with acute extradural
hematomas. A decision must be made now as to how
to manage the patient over the next hour. We give
dexamethasone (10 mg IV), although I am not at all
convinced that the patients are benefitted by it. If the
patient is in extremis, we give 1.5 mg/kg of hypertonic mannitol by IV push, in the hope of buying time
for angiography. We like to have angiography for all
of these patients as soon as possible. It must be
remembered, however, that if done within an hour or
two of the injury, one may miss the hematoma that is
in the process of developing. If the neurosurgeon in
charge feels that there is not time for an angiogram,
the surgeon may perform exploratory burr holes. We
avoid this operation if possible, since we feel that
angiography gives so much information. (The
technique mentioned in Dr. Vries' presentation of inserting a ventricular cannula, injecting some air, and
then treating the patient immediately, depending
167
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upon what that air study shows is impressive; if the
patient has a shift, take him directly to the operating
room.) If the patient does not have a mass lesion, a
Scott cannula is placed through a twist drill hole into
the anterior horn of the right lateral ventricle, in
order to measure intracranial pressure continuously.
If the patient goes to the operating room and has a
mass lesion removed, the Scott cannula is put into the
anterior horn of the lateral ventricle at the time of
surgery.
The patient is then returned to the neurosurgical
intensive care unit, where we go through a number of
procedures which will constitute the bulk of my discussion. Figure l is simply an artist's sketch of the
Scott cannula in the anterior horn of the right lateral
ventricle at the level of the coronal suture. Again,
Figure 2 is an artist's sketch of the patient in the intensive care unit with the head dressing and the Scott
cannula. The transducer is wrapped in a sterile towel
because there is a risk of infection from an insideoutside connection of CSF, and this requires
meticulous technique. In 350 cases, we have had an
infection rate of about 2%, which compares favorably
with Lundberg's 1.6% infection rate in something
Fig. 2

Fig. I

over 1,000 patients with continuous recording of intracranial pressure. We would like to get rid of the intraventricular cannula, because we consider 2% to be
still too high, but we do not feel, at this time, that
there is an adequate solid state transducer for
measuring intracranial pressure.
Figure 2 also shows a two channel strip chart
recorder. One channel records the intracranial
pressure and the other, systemic arterial pressure
from a catheter in either the radial or the brachia)
artery.
At this point, we prepare to do regional cerebral
blood flow and metabolism studies. We use the 133Xe
clearance technique, in order to measure regional
cerebral blood flow (RCBF). Xenon is injected
through a catheter placed under fluoroscopic control
into the internal carotid artery and the xenon is then
injected as a bolus. The xenon enters the brain,
diffuses into the brain tissue, and is then cleared from
the tissue over a period of about 15 minutes. The rate
of clearance from each region under study determines
the blood flow; therefore, the faster the rate of
clearance, the faster the flow. There are a number of
ways of examining and analyzing these clearance
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curves. We feel, for our purposes, that eight probes
for measuring RCBF over each hemisphere are perfectly adequate. There are, however, extremely
sophisticated systems in which it is possible to
measure the RCBF from as many as 250 regions.
In addition, a second catheter is placed percutaneously into the jugular vein and passed well up
into the intracranial space, into the sigmoid sinus, in
order to obtain a cerebral venous blood sample.
Periodically during the course of the clinical investigation, simultaneous samples of blood are taken
from the artery (from the internal carotid artery, in
this case) and from the jugular bulb, from which it is
possible to calculate the cerebral metabolic rate of
oxygen (CMR 0 ). Studies on the cerebral metabolic
rate of glucose, 2lactate, and pyruvate have been done
as well. In fact, if one's techniques are sophisticated
enough, accurate enough, in theory at least, it is possible to measure anything that the brain utilizes l:Jy
measuring the content in both the arterial blood and
the cerebral venous blood. Here we shall discuss only
CMR 0 , , oxygen utilization . First, we determine the
0 2 content in both the arterial and venous samples;
CMR 0 is equal to the arteriovenous difference of
oxygen' content times the mean cerebral blood flow
divided by 100.
Table I shows a selection of the normal values,
such as CBF, approximately 50 ml/100 gm/ min,
systemic arterial pressure, about 85. We defined, as
have others, normal intracranial pressure as less than
200 mm CSF or less than 15 mm Hg. The cerebral
perfusion pressure, assuming an ICP of 10, is 75 mm
Hg, the normal arterial-venous oxygen difference
(A VD 0 ) is 7-a figure to remember. The CMR 0 is
3.5 ml/ JOO gm/ min and the normal values for arte;ial
blood gases and pH are familiar to you.
For the sake of example, a single patient will
now be described in detail.
A 50-year-old man had been found on the street
and was brought into the emergency ward comatose;
he had bruises about the head, indicating that he had
been bludgeoned, and there were clinical signs pointing to a left hemispheric mass with evidence of
transtentorial herniation . He was given dexamethasone and mannitol and was intubated and ventilated with the Ambu® bag. The resident who was
caring for him felt that he was in extremis, that there
was not enough time to do an angiogram, despite the
administration of mannitol; therefore, the patient
was taken to the operating room for burr holes.
There was no evidence of an extracerebral
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TABLE I

Normal values of variables tested
Variable
cerebral blood flow (CBF)
systemic arterial pressure (SAP)
intracranial pressure (ICP)
cerebral perfusion pressure (CPP)
cerebral vascular resistance (CVR)
arteriovenous blood oxygen content
(AVDO,)
cerebral metabolic rate (CMRC,)
arterial carbon dioxide partial
pressure (PaCO,)
arterial oxygen partial pressure
(PaO,)
arterial blood acidity (pH)

Normal Value
50 ml/100 gm/min
85 mm Hg
15mmHg(200
mmCSF)
75 mm Hg

1.70
7.0 vol %
3, 5ml/100 gm/min
40mm Hg
100 mm Hg
7.35

(Reproduced by permission of the American Association of
Neurological Surgeons, and the authors, from D. A . Bruce, et al,
" Physiological Changes in Brain During Coma," J Neurosurg
38: 133 , 1973.)

hematoma; the resident needled the brain one time
and got no blood, and the Scott cannula was put in
along with a solid state transducer to measure intracranial pressure. The patient was then taken to the
angiography suite, where we also do the RCBF and
metabolism studies. On angiogram, the patient had a
huge, temporal and deep mass in the hemisphere. The
Scott cannula was, in this case, placed through a burr
hole in the lateral ventricle. While the angiogram was
being developed , we carried out our first RCBF and
metabolism study.
Figure 3 demonstrates one of the ways in which
we display the data. You will note that this patient,
during the control period, had a mean CBF of 10
ml/100 gm/ min, one-fifth normal and far below that
ordinarily required to maintain brain function. The
patient's mean systemic arterial pressure was 135 mm
Hg, and the mean intracranial pressure extremely
high at 107 mm Hg, giving the patient then a cerebral
perfusion pressure (CPP) of 28. Note that at this
time, the Pa 0 is quite adequate at I 04 and the Paco is
slightly low. The value for CMR 0 -0.71-is one-fifth
normal. One can state as a gener~l rule, with the occasional rare exception, that any patient with CM Ro,
less than 1.0 probably will not survive.
The angiogram showed the huge mass which had
been missed in the operating room with the single
pass of the needle. The needle was then inserted into
the region of the mass and we obtained 70 cc of
blood. A second postevacuation study was per-
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because of the edema, we now saw his Pa0 dropping
also, from 104 to 75.
'
Despite the improvement in the CBF and some
evidence of clinical improvement, the patient's
CMRo actually fell from 0.71 to 0.39, which is barely
one-te~th of normal. We tried to raise his blood
pressure, hoping to improve his perfusion pressure
and further improve his CBF, then at 18. Figure 4
shows the response following angiotensin. We
brought his SAP up to 129 from 76, but the CBF increased only from 18 to 23, because, with the arterial
hypertension and the edema fluid, the intracranial
pressure has gone from 47 to 74 mm Hg. In order to
comprehend the pathophysiology of these patients,
one must measure nearly all of these variables.
Despite his marked hypocapnia and hyperventilation, his Pa0 is still only 67 because of his pulmonary
edema. We decided to give mannitol, and the patient,
in terms of CBF, responded dramatically; CBF went
from 23 to 38, perfectly adequate for a normally
metabolizing brain, and ICP dropped from 74 to 48.

Fig. 3

formed, disclosing the reduced mass with the estimated increase in CBF from 10 to 18 ml/ I00
gm/ min. In the region of the mass, where blood flow
was virtually obliterated, we had a fourfold increase
from 6 to 24 ml/100 gm/ min. The intracranial
pressure dropped from 107 to 47 mm Hg following
evacuation of the mass. If we were measuring only
the ICP, we might feel we had really accomplished
something. The systemic arterial pressure, however,
was being held up by a Cushing response, secondary
to the intracranial hypertension . Although we
markedly reduced the intracranial pressure, the blood
pressure fell equally, and the perfusion pressure went
only from 28 to 29; despite that, we did increase CBF
by 8 ml/100 gm/ min.
Now, however, another problem arose. The
patient, comatose but showing slight evidence of
arousal, went from flaccidity to some decerebrate
posturing; he also began to hyperventilate, driving his
Paco fro m 36 down to 23, but, at the same time, he
developed acute pulmonary edema. Even though he
was hyperventilating and producing hypocapnia,

Fig. 4
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Marked improvement in CBF occurred, despite the
fact that the patient's perfusion pressure dropped
from 55 to 46. A change in fl.ow, of course, will occur
with a change in perfusion pressure or a change in
resistance or with a change in both, and, in this case,
it is quite clear that the mannitol has reduced the
edema, thereby opening up the microcirculation and
permitting a marked improvement in CBF, despite
there being no significant change in the patient's
CPP. The Pa 0 and Paco were the same; the CMR 0
was fluctuating somewh~t.
'
We continued to battle his intracranial pressure,
which, however, continued to rise, and finally, as is
the rule in these cases, the intracranial pressure
equaled the blood pressure. At this point, the phenomenon of nonfilling of the cerebral circulation upon
angiography or injection of 133 X became evident. In
this situation, if one injects radio-opaque media into
the carotid artery, it will rise up into the internal
carotid (sometimes to the level of the siphon) and
then stop. A film taken 30 seconds or a minute later
will show the opaque dye still sitting in the carotid
artery, none having entered the intracranial space,
due to the fact that ICP equals SAP and, therefore,
CPP is zero. When this occurred in our patient, we
decided he obviously had all of the clinical criteria of
brain death. We decided, however, to manipulate the
blood pressure with a vasopressor agent, Levophed®,
to see whether we could possibly reestablish a perfusion pressure. These primary changes in systemic
arterial pressure, produced by altering the rate of drip
of a vasopressor agent, produced precisely equal
changes in the ICP. There was no way to reestablish
perfusion pressure by manipulating the arterial
pressure. In this patient who had a severe and, as it
turned out, irreversible brain injury, we were, by
various types of manipulations, able to raise his CBF
to something approaching a normal range, but too
late, and the patient died shortly after this study.
Now, just a few comments on intracranial
pressure. Until the publication of Lundberg's landmark monograph from the University of Lund in
Sweden in 1960, we generally thought oflCP as being
a steady phenomenon; intracranial pressure had been
measured only through the lumbar subarachnoid
space in the vast majority of patients. In 1963, we
demonstrated in experimental animals (using a slowly
expanding extradural balloon in the monkey), that
when the intracranial pressure rises by virtue of expansion of a mass, a dissociation occurs invariably,
between the supratentorial pressure and the pressure

of the lumbar subarachnoid space. Finally, with the
slow expansion of the balloon, when the intracranial
pressure reached the level of the blood pressure in the
monkey, lumbar subarachnoid pressure was normal.
We demonstrated that this also occurs in man. The
higher the intracranial pressure, the greater the brain
swelling, the less likely it is that the lumbar subarachnoid pressure will reflect that increased intracranial pressure. Many times in man, lumbar subarachnoid pressure is normal when the intracranial
pressure is from 50-100 mm Hg. It follows, therefore,
that one cannot use lumbar subarachnoid pressure to
determine the actual pressure within the intracranial
space. All pressure measurements today are done
directly from the intracranial space by one method or
another.
Lundberg then demonstrated that in many
patients, intracranial pressure is not a steady
phenomenon; in fact, there are tremendous fluctuations in pressure. He described what he called "A
waves or plateau waves, B waves, and C waves." For
the most part, these waves appear to be rather innocuous, there being, usually, no indication of
neurological deterioration. With the extremely
dangerous plateau wave, the intracranial pressure is
reasonably steady, at first, but then fluctuates, and
finally, inexorably rises-a terminal pressure wave.
Figure 5 summarizes work that we did some 10
or 11 years ago. It is a very simple figure but quite important. This is the volume pressure graph within the
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intracranial space, actually taken from a series of
monkeys. We put in an extradural balloon, and then
slowly inflate it at a rate of l ml/min, while we
measure the intracranial pressure. Up to a volume of
about 5 ml in the balloon, there is no significant
change in intracranial pressure. Why is this? Because
the intracranial space contains displaceable fluid,
mainly in the form of CSF but also, to some extent, in
the form of intravascular blood. Since we are dealing
with a cavity that is nondistensible, which is filled to
capacity with a noncompressible fluid and solid
material, it follows that if indeed we had a completely
closed system, that is, if we had a sphere made of
bone filled to capacity with water, and we attempted
to inject additional water into that cavity, we could
probably inject no more than 0.1 ml, in the case of the
monkey; we would get a tremendous rise in intracranial pressure, simply because we cannot stretch
the shell. We cannot compress the fluid. That is not
the case in life. We can actually put 5 ml of fluid into
this monkey's skull (total capacity of 100 ml),
because of spatial compensation. It means that up to
a value of about 5 ml, for every l ml that we are putting into the balloon, we are expressing l ml of CSF
or blood. Then we pass from this period of spatial
compensation, the horizontal portion of the volume
pressure graph, onto the vertical portion. Note here
that between a balloon volume of 7 and 8 ml, the intracranial pressure rises 75 mm Hg. Thus, in the case
of those patients with pressure waves, those who have
any kind of mass lesion or brain edema, the bulk of
them are somewhere on the vertical part of the graph.
The pressure waves are due to spontaneous
alterations in cerebral blood volume. The pressure
waves are reflecting alternating vasodilatation and
vasoconstriction of the cerebral vascular bed. We do
not know the reason for this. The vasodilatation
produces a slight increase in cerebral blood volume.
That slight increase, however, when the patient is on
the vertical portion of the volume pressure graph, will
produce a tremendous change in pressure. The
patient who presents with a longstanding spaceoccupying mass, chronic subdural hematoma or
meningioma, who has now reached the limits of his
period of spatial compensation, therefore, may have
few signs or symptoms, but he is sitting on a time
bomb as it were. When he goes to sleep, for example,
he becomes a little hypoxic and hypercapnic. We
recorded many of these patients in sleep, and indeed,
their intracranial pressure may rise astonishingly during sleep, simply because of a little bit of vasodilata-

tion from the hypercapnia. It follows as well, that if
one is treating a patient who is on the vertical portion
of the curve, it is necessary to remove only a small
portion of any one of the volumes within the intracranial space in order to drop the pressure. We
have many patients who have had pressure of 80-90
mm Hg. The removal of no more than 2 ml from the
ventricle will drop the pressure down to 20-30 mm
Hg, because they are falling on an extremely sharp
vertical portion of the curve.
What constitutes a critical level of intracranial
pressure for brain function? I have no idea, because it
varies so much from patient to patient. The more the
brain itself is damaged, that is, the more the edema,
the more contusion, then the less tolerant that patient
is of intracranial hypertension. We have many
patients, for example, who would not tolerate an ICP
above 25-30 mm Hg; they would obtund, develop a
hemiparesis. When we then lowered the pr~ssure to
10-15 mm Hg, they would improve. Patient~who do
not have brain damage but, nevertheless, have intracranial hypertension, will often tolerate extremely
high levels of intracranial pressure. We have seen a
young woman with severe hydrocephalus from a
cerebellar hemangioblastoma. She was neurologically
normal, except for minimal ataxia and some
papilledema-her brain was normal. We recorded
her intracranial pressure continuously through the
Scott cannula and then slowly drained the ventricles
over a period of two or three days, as we always do
before doing posterior fossa surgery in these people.
We also recorded and checked the systemic arterial
pressure from the catheter in the the radial artery.
For very long periods of time, the patient had a CPP
as low as 6 mm Hg, the mean intracranial pressure,
85, and the mean arterial pressure, 91; this particular
time, she was in the intensive care unit, sitting up
reading a magazine, completely asymptomatic. This
is an indication of the phenomenal degree of
autoregulation that can be seen clinically.
If a hypertonic solution such as mannitol has
been given to a patient without causing reduction in
his intracranial hypertension, we might conclude that
mannitol has been of no benefit, and not give it to
that patient again. We might say that the patient is
refractory to mannitol.
Often this is not the case, and the patient improves despite no major ICP fall. How can this be?
We postulate that mannitol has reduced edema.
Reduction of the water content in the brain alone,
obviously, should result in decrease in intracranial
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pressure, but if one has compression of the microcirculation of the capillary bed in the venules by the
edema, and one reduces the edema, what is going to
happen to the cross-sectional area of the vascular
bed? It will enlarge as the compression is relieved.
Our guess is that as we remove the edema from the
brain with the mannitol, the edema is being replaced
by intravascular blood secondary to expansion of the
cerebral vascular bed. The net intracranial volume
remains the same, and intracranial pressure does not
decrease. What these data clearly show is that one
cannot use intracranial pressure alone to determine
whether or not mannitol nas had a beneficial effect on
the patient; one must, unfortunately, measure CBF.
The first indication for the use of mannitol
therapy, in our opinion, is for reducing brain bulk
during craniotomy, and second, for reducing ICP to
permit time for emergency cerebral angiography. The
third indication for its use is control of ICP during
continuous recording of ICP. I believe that the intermittent, or perhaps even the continuous, use of mannitol in these patients without continuous recording
of intracranial pressure is very dangerous, because if
the patient has a hemorrhage, a hematoma that is expanding, reduction of the intracranial pressure causes
further expansion of the hematoma; then, as the osmotic gradient is reversed, fluid comes back into a
space reduced by the enlargement of the hematoma.
This kind of situation can kill the patient quickly.
I will conclude by saying that I think the continuous measurement of intracranial pressure in the
proper management of patients not only with severe
head injuries, but with severe brain insults as well,
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has passed now from being a research tool to a virtual
necessity. I cannot say the same thing, yet, about
measurements of RCBF and cerebral metabolism, as
we are now caught in an ethical bind. We have four
or five RCBF runs, or consecutive studies, done on
patients over several hours. Rarely have we been able
to repeat these studies, because we did not feel justified in repuncturing the carotid artery, unless it was
necessary to do an angiogram on the patient. My
contention is that we would learn much more from
one patient with severe brain injury who has ten CBF
studies over a period of several days than we would
learn from ten patients who have one study each. In
order to prove that these techniques, which are expensive and time consuming, are really going to help
us in the management of these patients, we now need
to have a reliable noninvasive technique for doing
RCBF. These techniques are now available, particularly in the form of either inhalation or intravenous injection of 138Xe, but the mathematics are
extremely complex and must be done with a
laboratory computer, but I think they are promising.
In our neurosurgical intensive care unit, we are just
beginning to compare the carotid injection of xenon
with the inhalation of xenon, to see how well the
results correspond in our patients with severe brain
injuries. Ifwe obtain a reliable noninvasive technique
and can repeat the RCBF studies every hour, day and
night for as long as we wish, with no harm whatsoever to the patient, we will then be able to provide
the intensive treatment for these patients and the
evaluation of the therapy to which we have looked
forward for so long.

Continuous Intracranial Pressure
Monitoring in Patients with Brain
Injury: Technique and Application*
JOHN K. VRIES, M.D.
Assistant Professor of Neurosurgery, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University, Richmond

In 1971, a twist drill technique for measuring intracranial pressure (ICP) in patients with severe brain
injuries was introduced at the Medical College of
Virginia (1) . Shortly thereafter continuous ICP monitoring utilizing the ventricular catheter technique
of Lundberg was begun (2). It rapidly became
evident that knowledge of the ICP in this group of
patients speeded definitive diagnosis, provided an
early warning of developing mass lesions before
clinical signs appeared, and provided an objective
assessment of therapy directed against brain edema;
however, continuous monitoring by the Lundberg
technique was cumbersome to perform and carried a
significant risk of meningitis. In 1972, a new method
of monitoring ICP was developed at our institution
(3). The new method was based Cin the establishment
of a fluid connection with the cerebral subarachnoid
space by means of a special hollow screw. The
technique proved much simpler and safer than the
Lundberg technique. The development of this
technique combined with the completion of a sevenbed neurosurgical intensive care unit extended ICP
monitoring to all patients at our institution with
significant head injuries. The morbidity and mortality
for severe head injury have steadily declined as the
scope of patient monitoring has increased over the
last three yeats. We now consider ICP monitoring an
essential part of head injury management.

* Presented by Dr. Vries at the 27th Annu al Sto neburner Lecture Series, February 8, 1974, at the Medical College of Virgini a,
Richmond .
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Methods. Head injury patients are divided into 3
categories upon arrival at the emergency room based
on their level of consciousness. Patients who are comatose upon arrival or patients with whom no verbal
communication can be established are designated as
severe (grade 3). Patients who are lethargic, but with
whom verbal communication can be established, are
classified as moderate (grade 2). Patients who are
fully awake are classified as mild (grade 1). The presence of any focal neurologic signs increases the severity by one grade.
Grade 3 patients have an immediate twist drill
ICP measurement. A twist drill hole three-sixteenths
of an inch in diameter is made at the level of the coronal suture under local anesthesia . A ventricular tap
is then performed with an 18 gauge blunt ventricular
needle. ICP is measured by connecting the needle to a
water manometer. After obtaining the ICP, 5-10 cc
of air are exchanged into the ventricles and a brow-up
ventriculogram is obtained to assess shift of the
midline structures, Further management of these
patients is based on the results of this examination . If
the ICP is greater than 10 mm Hg and the midline
structures are shifted, the patient is given 1 gtn/ kg of
mannitol and is taken to the operating room for an
exploratory craniotomy. If the ICP is greater than 10
mm Hg and the midline structures are not shifted, the
patient is taken to the angiographic suite for
angiography . If the ICP is below 10 mm Hg and the
midline structures are not shifted, the patient is
taken to the intensive care unit and an elective
a ngiogram is obtained. Continuous ICP monitoring
MCV QUARTERLY 10(4): 174-177, 1974
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is performed on all grade 3 patients after they arrive
at the intensive care unit.
Grade 2 patients are taken to the angiographic
suite for immediate angiography. If a surgical mass
lesion is discovered, the patient receives l gm/kg of
mannitol and is taken to the operating room for a
craniotomy. If no surgical mass lesion is found, the
patient is taken to the intensive care unit. Continuous
ICP monitoring is performed in all grade 2 patients
after they arrive at the intensive care unit.
Grade I patients are admitted for close observation. If any clinical deterioration is noted, they are
managed like grade 2 patients.
Continuous ICP monitoring is performed by
means of a special hollow screw which permits fluid
contact to be made with the cerebral arachnoid space.
The screw is shown in Figure I. The screw is inserted
by threading it into the skull through a one-fourthinch twist drill hole, after the dura has been removed
with a small angled curette under direct vision. This is
illustrated in Figure 2. ICP is monitored by connecting the lumen of the screw to a transducer by means
of saline-filled tubing. The screw is shown in place in
the x-ray of a postoperative patient in Figure 3. A
typical ICP record, along with the blood pressure,
central venous pressure, and EKG, is shown in Figure
4. The ICP is displayed at each bedside on a wall
mounted oscilloscope, and it is written out at a central station on a strip chart for a permanent record.
A maximum effort is made in grade 3 patients,
after they arrive at the intensive care unit, to keep the
important systemic physiologic parameters within
normal ranges. All patients in this grade are placed
on a regimen of thorazine, 25 mg IM every 6 hours,
to help accomplish this. All patients in this category
have endotracheal tubes or tracheostomies. They are
placed on volume respirators and nursed in the level
position on heat exchange mattresses. On this
regimen, blood pressure can usually be adjusted by
raising or lowering the head of the bed, blood gases
and pH can be regulated by adjusting the respirator,
and the temperature is easily regulated with the heat
exchange mattress.
Patients who have progressive brain edema,
manifested by a steadily rising ICP after correction of
any systemic abnormalities, in whom surgical mass
lesion has been ruled out angiographically, are
treated with ventriculostomy drainage and hyperventilation to a Pco, of 25 mm/Hg. If this fails to control
the ICP, the patient is cooled to 30°C. If ICP still
cannot be controlled, a mannitol infusion at a rate of
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Fig. I

0.1-0.3 gm/ kg/ hr is begun provided the serum osmolarity does not exceed 320 mOsm/ L (4).
Results. In 1973, twist drill ICP measurement
and ventriculogram were used in 96 grade 3 head
trauma patients to establish a working diagnosis. On
only one occasion was there failure to tap the ventri_cle. There were no recognizable complications related
to the procedure. The average time required to perform the procedure was 10-15 minutes including the
taking of x-rays. Fifty-eight of the 96 patients had
elevated ICP and a shift of the ventricular system. All
58 patients had a surgical mass lesion confirmed at
operation. Eleven patients had normal ICP and a
midline ventricular system. None of these patients
developed a surgical mass lesion. Twenty-seven
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Subarachnoid
space
Pia

Fig. 2
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Fig. 3

patients had elevated ICP and a midline ventricular
system. Twenty-six of the 27 did not have surgical
mass lesions by angiography. One patient in this
group had an acute subdural hematoma on one side
and a brain contusion with edema on the other side,
giving him elevated ICP but a midline ventricular
system.
Since November 1972, ICP monitoring using the
hollow screw technique has been performed 161
times. It has been performed 102 times for head
trauma. In the vast majority of cases, a satisfactory
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recording of the ICP has been obtained, manifested
by a good wave form on the oscilloscope trace. The
average patient was monitored for seven days. The
complications to date consist of four patients with
superficial scalp infections, requiring local debridement, one CSF leak, requiring revision of a scalp incision, and one subdural hematoma, which occurred in
a patient who developed a bleeding disorder after insertion of the monitor.
The ICP monitor provided warning of developing mass lesions in all cases where such lesions
developed. Even though grade 3 patients were heavily
sedated, which tended to obscure the clinical picture,
no case of unsuspected mass lesion occurred. The use
of high doses of morphine and thorazine made the
management of the group 3 patients much easier.
Problems of temperature control, severe hyperventilation on a neurogenic basis, and erratic blood
pressure swings, for the most part, were eliminated.
With improved control of systemic physiologic
parameters, the need to resort to special regimens for
the control of progressively increasing intracranial
pressure was obviated. In 1972, 18 of these regimens
were employed. In 1973, only one regimen was
employed, even though more grade 3 patients were
seen in 1973 than in 1972.
Discussion. Twist driil ICP measurement and
ventriculograni appear to significantly speed the
definitive diagnosis and treatment of severe head injury patients in the emergency room. The procedure
had a high accuracy for differentiating betwe«n surgical and nonsurgical mass lesion. It can be accomplished in 10-15 minutes, which is much faster
than an angiogram under the best of circumstances.
It is easy to perform in the patient with multiple
trauma, because it does not require that the patient
be moved or transported to an angiographic suite.
Moreover, in some grade 3 patients, it is safer
because it does not require the degree of patient
restraint and positioning that an angiogram requires
which may produce jugular compression, or airway
obstruction.
Continuous ICP monitoring using the hollow
screw technique has proven itself simple, safe, and
reliable. The obvious advantage of continuous ICP
monitoring is to provide early warning of developing
mass lesions before clinical signs appear and to assess
the effectiveness of therapy directed at brain edema.
Its most important use, however, may be that it permits the use of depressant medications in these
patients. Many of these patients have a marked
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tendency toward hyperthermia, severe hyperventilation, and erratic blood pressure swings. These
tendencies can be most difficult to control with conventional treatment regimens. By sedating these
patients, however, it is easy to override these tendencies with a respirator, a simple heat exchange mattress, and patient positioning. In many of these
patients, all of the intracranial compensatory
mechanisms for the maintenance of brain metabolism
have been maximally taxed. These patients cannot
tolerate the additional stress of disordered systemic
physiology. At the present time, we try to hold our
severe head injury patients within the following
physiologic limits: cerebral perfusion pressure (blood
pressure-intracranial pressure) 75 mm Hg ± 10 mm
Hg; P0 85 mm Hg± 15 mm Hg; Pco 30mm Hg± 5
mm Hg; pH 7.4 ± 0.1; temperature 37° C ± 1° C;
sodium 140 ± 5; hematocrit 35 ± 5. Our preliminary
data seem to indicate that if this is accomplished and
if it is combined with rapid diagnosis and treatment
of surgical mass lesions, most cases of progressive
2
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brain swelling can be prevented. At the present time,
a prospective study of this regimen in head injury
patients is underway at the Medical College of
Virginia.
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N euro-Ophthalmology 1n Severe
Head Injury*
JOHN W. HARBISON, M.D.

Associate Professor, Department of Neurology, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University, Richmond

If asked what the significance of neuroophthalmology is in the evaluation of severe head injury, many medical and surgical practitioners of
neurology would promptly reply that it consists of
monitoring pupillary reactivity in anticipation of
the uncal herniation syndrome. A discussion of two
broad premises of a factual nature, however, should
easily convince these same practitioners that the
neuro-ophthalmic evaluation of patients with severe
head injuries offers far more than the Hutchinson
pupil.
Anatomically, the substrate of the eye-brain
mechanism is prodigious. It includes every cerebral
lobe, the basal ganglia, all divisions of the brainstem,
the cerebellum, half of the cranial nerves, and onethird of the spinal cord. The eye-brain mechanism
can be involved or interrupted at virtually any level of
the neuraxis. The resultant signs and symptoms
provide a kaleidoscope of pupillary abnormalities,
ocular motor disturbances of a peripheral and central
nature, and visual disturbances ranging from impairment or loss of acuity and field to complex perceptual
and associative visual disturbances.
The second factual premise is the extent of the
head injury problem. Six percent of all disabling injuries involve the head. Automobile accidents, but
one aspect of trauma, have a 66% incidence of head
injuries. Within the American population at large, it
is calculated that one person in two hundred will require medical care for head injury each year. Given

* Presented by Dr. Harbison at the 27th Annual Stoneburner
Lecture Series, February 8, 1974, at the Medical College of
Virginia, Richmond.
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the anatomic extent of the eye-brain mechanism and
the magnitude of the head injury problem, the incidence and variety of the neuro-ophthalmic signs and
symptoms of head injuries become mind boggling.
What can the neuro-ophthalmic aspect of head injuries provide in terms of patient evaluation and care?
In the initial evaluation of any head injury. victim, a thorough neuro-ophthalmic examination will
provide important clues to localization of sites of
trauma, whether they are primary or secondary,
direct or remote effects. Analysis of this information
will facilitate diagnosis and prompt, proper therapy
can be instituted. Despite these efforts, however, a
number of neuro-ophthalmic sequelae of head injury
will remain for the patient to recognize as he recovers
from more serious aspects of the head injury. Many
of the neuro-ophthalmic symptoms and signs
demonstrated go beyond simple signposts in directing diagnostic considerations, investigations, and
therapeutic endeavor. They serve a significant role in
prognostication of the patient's course and residual
neurologic and neuro-ophthalmic handicap. The
neuro-ophthalmic evaluation must not be limited to
the initial patient evaluation which may be not only
remarkably hectic but may also be restricted by
aspects of the trauma that either prevent adequate
evaluation or are of such a nature that they are lifethreatening and preclude neuro-ophthalmic evaluation. The neuro-ophthalmic examination should be
repeated at clinically appropriate points during the
hospital course and should be utilized as a monitor
for following the patient's long-term progress.
The value of the neuro-ophthalmic aspects of
trauma are not restricted to the primary care of the
MCV QUARTERLY 10(4): 178-182, 1974
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patient. Suitable documentation of the neuroophthalmic examination can be utilized during the
primary patient care and follow-up as a tool in
achieving a better understanding of the basic
mechanisms of brain injury. During recent years at
the Medical College of Virginia, close cooperation
between neurosurgery and neuro-ophthalmology has
provided the opportunity to implement this concept.
We are presently compiling data, helpful not only
in primary patient care but also in understanding the
basic mechanism of brain injury.
The broad extent of the neuro-ophthalmic
aspects of brain injury has been emphasized but space
prohibits comprehensive discussion of its full range.
An attempt, therefore, will be made to illustrate
selected aspects of the neuro-ophthalmic consequence of brain injury which may be both of interest
and benefit.
An appropriate beginning to the discussion of
neuro-ophthalmic consequences of trauma is the consideration of the concept of preexisting brain disease
as a precursor to trauma. Eyster clearly explained
that minor head trauma in the presence of basal intracranial tumors may well produce unexpected
neuro-ophthalmic signs of an oculomotor nature.
Other neuro-ophthalmic signs can be produced by
trauma and appropriately situated tumors. It is also
clear that previously undiagnosed intracranial
pathology may increase a patient's vulnerability to
traumatic incidents. In a similar vein preexisting signs
of a neuro-ophthalmic nature, either recognized or
unknown, though unrelated and clearly independent
of the traumatic incident, may cause significant
diagnostic consternation.
In introducing the topic, neuro-ophthalmology
of severe head injury, it was noted that perhaps the
most commonly sought neuro-ophthalmic sign of
trauma was a pupillary abnormality. The abnormality
most feared is the Hutchinson pupil-the dilation
of the pupil ipsilateral to a mass lesion, producing
transtentorial uncal herniation with third nerve impingement. It is generally an evolving sign, although
it may be present by the time of the patient's initial
medical attention. Because of its sinister import, it
must be differentiated from a similar pupillary abnormality-traumatic mydriasis.
Patients with severe head injuries also frequently receive direct blows to the eye. With direct blows to
the globe, contusion of the iris may occur which
results in a dilated and fixed pupil, usually unilaterally. If seen early, the initial response to the contusion

179

will be miosis; dilation and iridoplegia follow within
minutes, however, and may last minutes, hours, days,
or may be permanent. Often other signs of periorbital
trauma will point to the correct diagnosis of
traumatic mydriasis. In selected cases, however, it
may be impossible to differentiate a Hutchinson pupil
from traumatic mydriasis. In these situations investigations to rule out the transtentorial herniation
syndrome are imperative.
Oculomotor nerve palsies in head trauma are
common; they are also significant parameters for
localization and valuable monitors of the evolution
of the trauma patient's course. Their diagnosis is
most difficult in the comatose patient. In this situation, the third nerve paralysis is most easily
recognizable, basically, because of the prominent
features ofptosis, mydriasis, and generally prominent
deviation of the eye downward and outward. Sixth
nerve palsies are less readily documented and fourth
nerve palsies are almost never recognizable in the
presence of coma. The oculomotor evaluation in .
comatose patients, however, is facilitated with the use
of doll's head phenomenon and caloric responses.
Differentiation of primary and secondary palsies is of
great practical significance to the physician responsible for the care of the trauma patient. Oculomotor
palsies, as primary traumatic injuries, are almost
always present immediately. Secondary palsies,
reflecting an evolving intracranial mass, generally occur many minutes to hours or days later. If the
trauma patient is delayed in receiving medical attention, or if the initial examination is incomplete, this
differentiation may not be possible.
Clearly, early and accurate evaluation and
documentation of ocular motility, as well as its continued monitoring during the patient's recovery, is
important. The ophthalmologist, who must commonly deal with the motility disturbance at a time distant
from the injury, may be extremely dependent upon
this documentation for his analysis and decision
regarding surgery of the paretic muscle. It is currently
recommended that surgery on paretic muscles be performed at any point after the fourth month, if maximal improvement has occurred. Statistics on the incidence of oculomotor involvement in trauma are less
reliable than is desirable, due largely to misdiagnosis.
Involvement of the third and sixth cranial nerves is
probably neady eqµally common. Fourth nerve injury is distinctly less common.
Third cranial nerve palsies are the result of
significant frontal injuries generally associated with
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concussion and skull fracture; they may be isolated
sequelae of trauma. The site of third nerve injury is
probably at its point of ·dural penetration at the
posterior aspect of the cavernous sinus. The
mechanism of injury is probably by virtue of shearing
and stretching forces exerted upon the nerve with
movement of the brainstem and skull base.
Traumatic third nerve palsy is almost always unilateral, bilateral involvement being so rare as to
suggest an additional pathologic process. Aberrant
reinnervation is common in traumatic third nerve
palsy and generally becomes evident at two-to-three
months after injury. Lid and pupil signs are easily
recognized.
Although fourth nerve palsy is less common
than third and sixth nerve injury, it is by no means
rare. It is easily missed. Fourth nerve involvement is
often bilateral. Usually, it is the result of a vertex or
frontal blow in which the dorsal midbrain and
anterior medullary velum are contused on the tentorium. Motorcycle accidents are the common inciting event and permanent dysfunction is not uncommon.
Sixth nerve palsies commonly occur with frontal
blows; they may be bilateral and, if the mode of onset
is unknown or not documented, it may be impossible
to differentiate direct injury of the sixth nerve from
the secondary effects of increased intracranial
pressure. Injuries producing sixth nerve paralysis
may be based upon the presence of petrous ridge fractures. In this circumstance, associated paralysis of the
seventh and eighth cranial nerve is common.
Injuries producing fractures of the superior orbital fissure frequently result in combined involvements of the third, fourth, and sixth cranial
nerve. Such injuries have associated optic nerve injury and visual loss 50% of the time. Trigeminal and
facial nerve injury occur an additional 25% of the
time.
Frontal and superior orbital fractures may be
associated with ptosis and elevator palsy due to
paresis of the superior rectus. Although this is the
superior division of the third nerve, it indicates involvement at a different site-within the orbit.
Associated involvement of the superior oblique as
well as the optic nerve may occur.
Also to be distinguished from true third nerve injury is the elevator palsy caused by the incarceration
of the inferior rectus in "trapdoor" fractures of the
orbital floor. This, as part of the orbital blow-out
fracture syndrome, is usually associated with

enophthalmos and sensory loss in the distribution of
the inferior orbital nerve.
Supra- and internuclear ophthalmoplegia, from
brainstem contusion on the free edge of the tentorium
or from other less clear mechanisms, may be confused with partial third nerve injury. Their
characteristic appearance and a knowledge that they
may occur will usually avoid confusion.
The presence of a congenital Duane's retraction
syndrome may cause confusion by its resemblance to
a traumatic sixth nerve injury. Past history and the
characteristic refraction of the globe with associated
narrowing of the palpebral fissure on adduction will
usually assist in the distinction. In a comatose
patient, differentiation may not be possible.
The presence of obvious evidence of local orbital
injury will generally suffice to distinguish oculomotor palsies of myogenic origin based upon local
hemorrhage, contusion, and laceration of muscle.
Obviously they may coexist with nerve injuries and
their separation may be impossible.
Finally, one must recognize that skew deviation
and wandering, dysconjugate eye movements are
common in the coma of concussion. They are felt to
represent disruption of oculomotor integration by the
same mechanism responsible for the alteration of
consciousness-physiologic alteration of the reticular
formation. With return of consciousness, oculomotor
function also returns to normal.
That blindness-visual loss-is a common result
of head injury, is reflected in a quotation attributed to
Hippocrates: "Dimness of vision occurs in injuries to
the brow and in those placed slightly above." Visual
loss can occur at any point in the visual pathways. It
is most commonly encountered, if we exclude the eye
itself, at the beginning and end of the intracranial
pathways-the optic nerve and the occipital cortex.
The differentiation of optic nerve and cortical
blindness is seldom a problem. The exact definition of
the mechanism of visual loss in both may be difficult
yet extremely important.
The mechanism of optic nerve injury is varied.
Generally, the blow is severe but may be extremely
mild. The site of injury is most frequently the optic
foramen, with involvement of contiguous orbital and
intracranial optic nerve. Despite this localization, xrays are seldom helpful. If visual loss is immediate
and severe, the mechanism is likely to have been tearing, nerve hemorrhage, or contusion necrosis. If
the onset has been delayed minutes-to-hours,
hemorrhage into the vaginal sheaths, secondary
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edema or vascular compromise may be responsible. It
is important to separate these two presentations since
delayed visual loss may indicate a situation reversible
by decompressive surgery. Immediate visual loss is
virtually never remediable by surgical decompression. Unfortunately, the time of onset of visual impairment is frequently clouded by unconsciousness.
Spontaneous recovery, if it is to occur, usually will do
so in a few days. Significant residual is the rule.
Another mechanism of optic nerve and chiasm
involvement in trauma is the compression of the
nerve and chiasm against the sphenoid bone by the
posterior orbital convolutions. The gyri recti may actually shift into the anterior chiasmal angle.
Resulting visual loss with central scotomas or bitemporal field defects may not be recognized by virtue of
altered consciousness. This syndrome is frequently
associated with diabetes insipidus.
Cortical blindness results basically from two
mechanisms-direct injury to the occipital cortex and
infarction secondary to vascular compromise by
the transtentorial herniation syndrome. Cortical
blindness is a frequent result of a direct blow to the
occiput. The resulting blindness is seldom permanent
and usually resoives in minutes, hours, or days.
Although recovery is often complete, residual visual
field defects may occur. When they do, they are
homonymous and frequently consist of congruous
paracentral scotomas.
While compression of the third netve is well
recognized in transtentorial herniation of the medial
temporal Jobe with asymmetric supratentorial
traumatic mass effects, compression or "pinching" of
the posterior cerebral arteries with infarction of
calcarine cortex is not. The resultant homonymdus
hemianopsia or cortical blindness is infrequently
recognized because, again, there is usually coma. If
the homonymous defect is recognized, it is of
lateralizing value as it almost always occurs on the
side of the mass effect. Most commonly, they are first
recognized if and when the patient recovers.
The funduscopic examination in patients with
severe head injuries may reveal pathology of
diagnostic value. Several factors enhance the examiner's opportunity to obtain a satisfactory and
relatively complete evaluation of the patient's fundus.
Pupillary dilation may make the difference between
an adequate exam and complete failure to visualize
the fundus. Obviously, the decision to dilate the pupil
of a head-injured patient must not be taken lightly
and will depend upon a variety of factors. With the
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utilization of modern methods of evaluation and intracranial monitoring, an appropriate dilated examination is more feasible. It remains imperative to
note on the patient's bed and chatt what has been
done and when. Another invaluable factor is adequate illumination-a bright light.
Papilledema, previously felt to be relatively uncommon in closed head injury, may occur far more
frequently than suspected in a mild form _lasting
several days. Occasionally, hidden globe perforation
may occur, resulting in hypotony-low intraocular
tension. This may produce disc edema. The syndrome
will be unilateral.
The appearance of preretinal hemorrhages in the
fundus of a head-injured adult usually reflects a
severe head injury with significant subarachnoid
blood. The presence of a hemorrhagic retinopathy
with prominent preretinal hemorrhages in an infant
suggests several possible causes, the most prominent
of which is the presence of subdural hematomas. It
has been estimated that one-half of infants with subdural hematomas have intraocular hemorrhages.
Their significance is that they are relatively unrelated
to the severity of the infant's presenting symptoms.
The child may appear only mildly ill yet harbor subdurals. The association of subdurals with the battered
baby syndrome gives the fundus picture of preretinal
hemorrhages added significance. The severity of the
preretinal hemorrhages is highly variable; severe
hemorrhage is common, however, and on occasion
may fill the vitreous. Their presence is generally
bilateral. The prognosis is also variable. In extreme
cases, fibrosis may occur with traction and retinal
detachment. They most frequently clear without
significant residual.
Commotio retinae or retinal contusion results
from severe direct blows to the globe itself. Abrupt
rises in intraocular pressure occur, with distortion
and shearing forces affecting intraocular structures.
The resulting contusion necrosis with cloudy gray
swelling, usually affecting the maculae and posterior
pole, generally culminates in severe permanent visual
impairment.
Many patients with severe head injuries suffer
additional trauma to other parts of the body. Specific
types of injuries result in characteristic retinal
pictures.
In compression or crushing chest injuries, the
resulting increased intravascular pressure is
transmitted to the eye producing a specific fundus
picture-Purtscher's retinopathy or traumatic retinal
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angiopathy. This consists of multiple superficial
cotton-wool spots, of one disc diameter or less in size,
generally located in the posterior pole between
arterioles and veins. Associated retinal and preretinal
hemorrhages are the rule. Initial visual impairment is
variable but usually significant. The fundus picture
may be delayeq two-to-three days. The course is
usually one of progressive return to normal over
weeks to several months.
The occurrence of retinal fat emboli in fractures
of long bones is frequently overlooked since the
patients are either comatose or have no visual symptoms. The retinal picture consists of several small
cotton-wool exµdates, usually but not invariably,

fringed by hemorrhage as well as additional retinal
hemorrhages which usually occur in the posterior
pole but seldom affect vision. The presence of the
better known aspects of fat embolization should
facilitate their recognition.
In closing, a single classic and nearly diagnostic
external neuro-ophthalmic sign in head injury might
be mentioned. This is the so-called "panda sign" of
bilateral orbital ecchymosis restricted by the
palpebral fascia to the orbital margin resulting in its
nearly circular configuration. Its characteristic
purplish color and commonly delayed appearance of
two-to-three days are strong evidence of an anterior
cranial fossa fracture.

Advances 1n N euroradiology*
FREDERICK S. VINES, M.D.

Associate Professor of Radiology and Neurology;
Chief, Section of Neuroradiology, Medical College of Virginia,
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The development of two new radiological
techniques has significantly enhanced the performance of neuroradiological diagnostic procedures.
The first of these was installed as the prototype unit
at the Medical College of Virginia in November of
1972 and has marked advantages for the performance
of encephalography, angiography, and air myelography. The present communication will relate
the experiences of the author during the initial 15
months of clinical evaluation. The second technique
is an entirely new concept of obtaining further information from the data provided by the penetration of
x-ray photons. Each of these units will be discussed
briefly with an outline of the principle indications and
advantages of each system .
An lsocentric Diagnostic System. The principle
feature of this system is a fully isocentric unit (Omnitomet) maintaining the head in alignment for filming or fluoroscopy, regardless of the patient's position during 480° of continuous rotation (Fig. 1). ACarm rotates 300° about the isocenter. The L-arm
provides 270° of rotation parallel to the wall axis
with consequent alteration in the site of rotation of
• Presented by Dr. Vines at the 27th Annual Stoneburner Lecture Series, February 8, 1974, at the Medical College of Virginia,
Richmond.
t General Electric Corporation, Medical Systell)s Division ,
Milwaukee, Wiscon sin .
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the C-arm . This unit was designed primarily for
pneumoencephalography and enables one to obtain
standard film series as well as Gtossmart tomography
in the frontal or lateral views, as indicated, regardless
of the patient's position. A unique feature is the ability
to perform tomography at varying angles of incidence (Fig. 1-B). The brain stem may be
tomographed coronally, therefore, relative to its vertical alignment and areas such as the temporal horns
or corpus collosum may be viewed perpendicularly to
their long axis without movement of the head and
subsequent alteration in the position of the contrast
material. There is lateral, longitudinal, and vertical
adjustment of the chair relative to the isocenter, so
that once the isocenter has been established, the
patient may be moved to readjust as necessary
throughout the procedure. An image intensifier and
television system are incorporated into the C-arm,
allowing constant fluoroscopy regardless of the patient's position. The Omnitome system is also
equipped with a phototimed 105 mm camera
providing for either single or multiple frame, up to 12
per second, with fluoroscopic control. The unit may
be operated from the remote control panel or a
mobile hand control may be utilized with closer
observation of the patient. Television monitors are
available iii the control booth and adjacent to the
patient. The usual encephalogram includes standard
183
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Fig. IA.

Fig. IB.

Fig. l-Omnitome-C-arm-1; L-arm-2 A. Patient positioned for erect frontal views. B. Position for erect frontal view with L-arm angled. C.
Prone, A-P view. D. Normal lateral encephalogram tomogram . E. Coronal tomogram of right acoustic neuroma. Fourth ventricle (4) compressed and rotated. F. Coronal tomogram I cm anterior to E with mass adjacent to pons.

films in the erect and supine position with the
remainder of the film series obtained on the
photospot camera. This enables one to obtain multiple different projections and angulations with a
significant reduction in the time required to perform

the study. Both filming and positioning are done with
fl.uoroscopy, obviating the time required for changing
film cassettes.
An accessory table is utilized for air myelography on the Omnitome (Fig. 2). The technique

Fig. IC.

Fig. ID.
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Fig. IE.

Fig. IF.

emphasized by Heinz (I) has been used primarily
for study of the cervical spine. This technique is
usually utilized for patients with cervical fractures or
cervical spondylosis. Unstable cervical spine fractures are ideally suited for this study, allowing one to
maintain adequate skeletal fixation with the patient
supine. Degenerative disease of the cervical spine is
also well studied by this method, since the surfaces of
the spinal cord can be evaluated with tomography as
well as the ventral defects associated with
degenerative cervical discs. A lateral puncture of the
subarachnoid space is quite easily performed under
fluoroscopic control at the Cl-2 interspace. Filling of
the entire subarachnoid space is obtained with the
patient supine and in 20° Trendelenberg position.

The accessory table is also utilized for
angiographic procedures, with the C-arm providing
fluoroscopic versatility (Fig. 2-C). Vertical height adjustment of the table of 50 cm is available for
magnification studies. The table top may be motor
driven or converted into a free-floating surface with a
foot switch. Adequate distance is available for
femoral catheterization. Filming may be obtained on
the 105 mm camera or with standard film changers.
The 105 mm camera again is quite beneficial,
providing the capability of a "see-through" changer
with rapid serial filming available at all times during
fluoroscopy. The ability is also preserved to perform
multiple complex angle views rapidly. A second tube
may be positioned on a floor pedestal for bi-plane
filming if desired.
The indications for angiography on this unit are
necessarily determined by the availability of other
angiographic facilities. The principle advantage of
angiography on the Omni tome is the 105 mm camera,

Fig. 2A-Patient positioned for air myelogram
Trendelenberg.

in 20°

Fig. 2B-Normal lateral tomogram.
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Fig. 2C-Positioning for angiography for serial film changers
cephalad to patient.

Fig. 2D-Right bracial injection (105 mm).
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and therefore, cases are chosen where this would be
of significant benefit. Patients studied for spontaneous subarachnoid hemorrhage or extracranial
vascular disease are particularly suitable as are those
patients requiring selective spinal cord angiography.
Multiple views may be obtained with a significant
reduction in time to perform the study and consequent reduction in patient discomfort and complications . The possibility of obtaining a standard
film series in the optimal projection is available after
preliminary study with the 105 mm camera .
Angiotomography is also available as an ancillary
procedure, since the C-arm maintains its ability to
perform tomography wherever positioned.
Supplementary benefits of this system are multiple. One may obtain standard views of the skull or
cervical spine utilizing the orbiting system and
fluoroscopic centering. Obviously procedures requiring bi-plane fiuoroscopy such as ventriculography,
orbitography, or cerebral biopsies are simplified with
this facility.
Computerized Axial Tomography. The second
portion of this discussion will involve a new technique that has been variously . compared with the
discovery of penicillin or the first use of contrast
material to complement standard radiographic
techniques. Radiologi-sts have long recognized that
less than 10% of the information available on standard radiographs is actually interpreted by the physician. This new technique utilized computer analysis
of the x-ray photon transmission? making it possible
to analyze physical properties of normal cerebral
tissues and a wide variety of pathological lesions.
The prototype equipment was installed in 1971 ,
the first clinical reports appearing in 1972 by James
Ambrose at the British Institute of Radiology (2).
Since his initial reports, others have confirmed the
importance of this unit and its acceptance throughout
the world has been universal (3).
The patient lies on an adjustable couch with his
head enclosed in a cap projecting into a water contained box (Fig. 3-A). He is comfortable, -fully
dressed, and no additional contrast materials are
necessary. A slit x-ray beam scans the head using the
sodium iodide crystalphotomultiplier to detect the
photons. The detectors move in parallel with the xray tube across the patient's head with 160 readings
of photon transmission during each horizontal movement (Fig. 3-B). The entire frame then rotates one
degree and the horizontal movement is repeated. For
each parallel movement of the unit, therefore, 28,800
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Fig. 3-A. The EMI scanner. B. Rotation sequence of scanning unit. C. Patient positioned for tomograms to include orbits and posterior
fossa. D. Arbitrary scale of absorption values with air as - 500 and water as 0.

absorption readings are obtained, which the computer can analyze within five-to-ten minutes .
Routinely three or four axial sections are obtained
with two scans of each slice. The head may be
rotated to include the posterior fossa on the caudal
scans if clinically indicated (Fig. 3-C). These are normally 13 mm by 2.94 mm by 2.94 mm, but an 8
mm collimator may be used if desired .
The data may be stored in two forms for recall
when desired. A paper printout is available with
numerical values of the relative absorption

coefficients. There is also a cathode ray tube display
of the information in an 80 by 80 matrix form . A
Polaroid® camera is used for photographic records of
the cathode ray tube display.
The absorption values are a normal function of
the physical density and the atomic numbers of the
tissue analyzed. The relative absorption values are illustrated in Figure 3-D. Water is used as a reference
(i.e., water = 0) and the scale of relative percentage of
absorption of intracranial tissues is expanded several
times for convenience. Utilizing a gray scale picture
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Fig. 4-Normal axial tomograms beginning caudally (A) and
progressing superiorly. A . Caudal section . Broad white outer zone
is the skull . Petrous temporal bone (p) and orbits (0). Fourth ventricle is black area posteriorly (4).

Fig. 48-Ambient, interpeduncular and sylvian (s) cisterns.
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Fig. 4C-Frontal horns, third ventricle(!), and trigone of lateral
ventricles. Pineal calcification behind third ventricle and glomus
calcifications in trigone.

of each tomographic section, water density would be
black with increasing grayness-to-white at the bone
level. It can be seen that water density is adequately
separate and allows the basal cisterns and ventricular
system to be visualized with ease (Fig. 4). Likewise,
calcifications are very clearly delineated, such as in
the pineal gland or glomus of the choroid plexus. It
must be emphasized that this technique utilizing absorption coefficient differences and computer analysis
is much superior to the previously used photographic
methods and computer enhancement processing of
photographic images. Preliminary data indicate that
all of the cerebral tissue, cerebrospinal fluid, and
coagulated blood are very easily distinguished. The
matrix actually allows for analysis of individual 3 mm
lesions at any point of each tomogram.
The preliminary results obtained in this country
have confirmed the reasons for the rapid acceptance
of this dramatic new technique. The most striking
pathological change is with an intracerebral
hematoma (Fig. 5-A). The clotted blood is quite easily
seen, with its absorption coefficient in the 20 to 30
range, and extension into the ventricles or the cortex
is easily delineated . Cerebral infarcts must be
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Fig. 4D-Lateral ventricles.

Fig. 4£-Lateral ventricles.

differentiated during their various pathological
stages. The early lesion may be patchy with decreased
absorption and much larger definition occurring in
seven-to-ten days as the necrotic area becomes
sharply defined with the onset of phagocytosis.
Gliomas are highly variable not only from case
to case, but in different parts of the same tumor (Fig.
5-B). Cystic areas within the neoplasm may be seen
by the decreased absorption with areas of more dense
and compact tumor delineated by an increased absorption value. More importantly, one is able to
evaluate deep infiltration of a portion of tumor into
the critical deeper structures.
Metastatic neoplasms tend to be more circumscribed than the primary gliomas (Fig. 5-C). The
center may be necrotic and cavitated with a decreased
absorption or may be dense and compact with a large
surrounding area of cerebral edema and consequently
with deer.eased absorption.
The development of this procedure has significantly altered the evaluation of. patients with
cerebral dysfunction. One is now able to selectively
choose which patients will require the more invasive
but precise technique of pneumoencephalography

Fig. 4F-Cortical sulci.
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Fig. SA-Left thalamic hemorrhage (h) with frontal horn compression and shift.

Fig. SC-Deep right thalamic metastases with a cavitated center.

Fig. SB-Left frontal astrocytoma extending deep into basal
ganglia. A large cyst (c) is also present.

and angiography. There will also be fewer negative
results with these studies. The tomographic study
enhances other techniques and will enable isotope
brain scanning techniques to become more specific
with the development of tissue specific radionuclides.
The results from one center (3) indicate that of the
first hundred patients that underwent computer assisted tomography, 71 of them required one or more
neuroradiological procedures for diagnosis. In the
fifth group of 100, however, only 34 required further
study.
The expertise required to interpret this tomographic study is somewhat more than one would
anticipate. One must not only interpret the pathophysiological data, but he must also know the associated features and types of mass effect created by
different lesions. He must understand not only the occurrence of a glioma but its typical pattern and
course of infiltration as well as the types of cerebral
infarction and their sequential pathological development in time. He must also know what pathological
conditions are associated with cerebral edema or
necrosis, and how this may modify the absorption
values. Likewise, the initial feeling that differentiation of the gray and white matter could be attained
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with ease has been less commonly observed in prac·tice. The technical limitations in the evaluation of the
base of the skull and particularly the cerebellopontine
angles has been less impressive. Most investigators,
however, have now shown that with care this area can
be seen with certain limitations. Extracerebral hematomas were also considered to be a significant
problem with the use of this unit. Extradural hematomas with their larger portion of congealed
blood have easily been seen; however, subdural
hematomas have varied considerably and require
care of the observer in interpreting the results . Since
the hematoma may be totally liquid and therefore of
water density, the absorption may be considerably
different from a hematoma that is mixed in character
or contains more clotted blood and is more dense
than the surrounding cortex. Frequently there is also
adjacent cerebral edema which limits the exact
differentiation between the borders of the hematoma
and the cortex. Even with this limitation, however, it
is considered that with careful evaluation of the edges
of the lesion, the hematoma may be ascertained with
a high degree of accuracy. Even if the hematoma is
not delineated fully, the shift of the ventricular
system and cerebral structures is quite easily seen and
accurately indicates a source of the cerebral dysfunction .
There is no question that the avenues for research and further investigation available through
this technique are unlimited. Most importantly it is a
functional and clinically useful tool that can be performed safely on inpatients or outpatients with no
morbidity. The procedure may be conducted by an
experienced neurotechnologist after a short period of
familiarization with the method and equipment. The
limitations of this technique are negligible in view of
its outstanding advantages. There is clear indication
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that there will be a significant reduction in the
number of pneumoencephalograms, and in select
cases, angiography will also be omitted from the.
diagnostic evaluation. Carotid angiography will no
longer be necessary to evaluate an intracerebral
hematoma or hydrocephalus. Radionuclide brain
scanning will have a limited place in the diagnostic
evaluation. These are immediate benefits and only the
future will ascertain the long-term alterations in the
~valuation of patients with disease of the central nervous system.
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Advances 1n the Management of
Pituitary Tumors*
CHARLES B. WILSON, M .D.

Professor and Chairman, Department of Neurosurgery,
University of California, San Francisco

A new development in the management of
pituitary tumors is the transsphenoidal technique. It
will be my purpose to show that it provides an elegant
way of handling the great majority of pituitary
problems, at least the ones that I have encountered,
although it has its shortcomings as well as its
advantages .
Pituitary tumors manifest themselves in two
ways-by compressing structures in the neighborhood, primarily the optic nerves and chiasm
and by the two endocrine manifestations, one being
the compression of the normal pituitary gland to
produce varying degrees of hypopituitarism and the
other, the hyperfunctioning adenoma. A large tumor
with a suprasellar extension compresses the optic
chiasm and optic nerves; obviously, a tumor of this
size would also cause a degree of hypopituitarism. A
smaller tumor, a microadenoma, can express itself by
hypersecretion of a hormone before it has either
produced neighborhood signs or has compressed the
normal gland to produce hypopituitarism. A functioning microadenoma secretes an excess of a particular hormone; we have encountered three
neoplastic cell types that I will describe later.
We owe the transsphenoidal approach to Harvey
Cushing, who took up the procedure because at that
time it was safer than craniotomy. Dr. Cushing,
working with a headlight (looking very much like a
coal miner's lamp) and with a simple speculum,
achieved excellent results. He encountered two
problems-he was viewing a deep, dark hole without
* This is an edited transcript of a lecture presented by Dr.
Wilson at the 27th Annual Stoneburner Lecture Series, February 8,
1974, at the Medical College of Virginia, Richmond.
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magnification, and there was a CSF lead and
meningitis without the advantage of antibiotics. A
Frenchman, Guiot, is largely responsible for reintroducing the transsphenoidal procedure. One of his
brilliant students, Jules Hardy, refined the technique,
using the operating microscope and an image intensifier, which allows the operator, during the
procedure, to observe operative maneuvers in the
region of the sella.
The anatomical principles underlying the surgical approach to the pituitary are really two: One is
a sublabial-transnasal-transsphenoidal approach,
maintaining the strict midline which is of great advantage to the surgeon, because he can see equally
well to the right and to the left and he knows that he
is in the midline. The second is the image intensifier in
the lateral projection, because this permits the surgeon to look on the television monitor so that he can
approach the sella between the tuberculum and the
floor; he can see his instruments within the sella, and
he can put air in the ventricul~r systein at the beginning of the operation and watch the third ventricle
pulsate down into its normal position as the
suprasellar component of the tumor is removed. For
maximum safety, the image intensifier is essential.
With experience, one can see and identify the normal
pituitary gland, and the surgeon can be certain that
the suprasellar component has been removed,
because the nortnal intracranial pressure in a semisitting position forces the stretched diaphragm of the
sella (which we have erroneously referred to as the
tumor capsule in the past) back down into the sella,
so that with a sizable suprasellar extension, one actually ends up with a diaphragm almost pulsating on
the floor of the sella.
MCV QUARTERLY 10(4): 192-195, 1974
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Dr. Hardy has recently ·suggested that microadenomas of certain cell types occur in preferential sites within the anterior lobe. This has
not been our experience, but his larger experience is
more valid. The endocrinologists with their elegant
techniques can pick up endocrinopathies at an early
stage. Our neuroradiology had to improve to identify a microadenoma, when the endocrinopathy was
defined. This is particularly true, not so much in
acromegaly, but with the galactorrhea-amenorrhea
syndrome and postadrenalectomy Nelson's syndrome.
We are completing a paper on our experience
with the neuroradiology of microadenomas.
Although in the lateral projection, the sella is unremarkable, on plain films, lateral polytome cuts
show an obviously abnormal sella. With A-P
polytome cuts, one can predict the location of the
microadenoma because of depression and thinning of
the floor of the sella. The surgeon can expose the
microadenoma at the site of the focal sellar bulging.
A microadenoma is 1 cm or less in diameter.
These small tumors are ideally suited to transsphenoidal removal. One would not approach a
microadenoma with the classical transfrontal technique, since it is difficult to reach and involves going
through normal anterior pituitary at an awkward
angle to reach the adenoma.
I have removed 60 pituitary tumors by a
transsphenoidal approach; one-half presented with
hyperfunctioning adenomas. My experience with
these tumors has pushed me strongly in two directions: First, we have an extremely active endocrine
group and a large number of acromegalic patients; second, I work with a neuro-ophthalmologist, William
F. Hoyt, who attracts patients with unusual eye
problems, a fair number of whom have pituitary disorders. Approximately one-fourth ~f his patients had
clinical and chemical hypopituitarism at the time of
presentation-I I% complained of visual loss; 7%, of
diplopia; 6%, of headache; and 4% had rhinorrhea .
Regarding visual-field defects-58% had no defect, 32% had bitemporal hemianopsia or some
variation of that, and 10% had some other type of
visual-field defect.
By routine stains, 62% were chromophobe, 36%
eosinophil, and 2% basophil. In the chromophobe
group are some prolactin-secreting adenomas, some
growth hormone-secreting adenomas, and some
ACTH-secreting adenomas. According to functional
types, 40% secreted nothing or, at least, nothing that
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we recognized. I suspect, however, that this number
would be smaller, if we checked every patient for
prolactin levels, because elevated prolactin levels can
exist without any overt clinical manifestation . The
remaining 60% secreted an excess of one hormone:
14% prolactin, 10% ACTH, and the remainder,
growth hormone. All patients with ACTH-secreting
tumors had undergone prior adrenalectomy and
presented with hyper-pigmentation and high ACTH
levels.
With respect to anatomical extent of the tumors,
33% were entirely intrasellar. Some of these were
microadenomas; some were not. Even with very large
sellas, the tumor may be contained within the sella.
The remainder extended beyond the sella-some with
extrasellar extension in more than one direction-42% were suprasellar, 28% had eccentric lateral
extension, and 23% went into the sphenoidal
sinus. The number of sphenoidal and suprasellar
extensions is directly related to the quality of the
neuroradiology.
When we began using the transsphenoidal
technique, we got only the castoffs-patients who
had failed to respond to prior treatment. Ours was
the second team in terms of handling pituitary
problems, but as we demonstrated our ability to handle recurrent tumors, we began seeing primary cases.
As we gain greater experience with the acromegalic patients, we are reducing growth hormone
levels down to very low levels, like 2-3 ng/ml. Not
a single patient, primarily treated for acromegaly,
. has developed hypopituitarism following operation. Transsphenoidal removal constitutes excellent
treatment for acromegaly, and we are seeing more
and more patients. We are in the process now
of designing a study which will compare
transsphenoidal removal alone with transsphenoidal
removal plus irradiation. Unless postoperative
growth hormone levels are in the normal range, the
adenoma has not been removed. Because our experience is limited, we do not know how many of
these patients will return with late recurrence.
Patients with Nelson's syndrome have undergone adrenalectomy for Cushing's disease, and at
variable times thereafter, become hyperpigmented.
Many tumors that secrete ACTH are malignant in
the biologic behavior, which is a compelling reason to
make the diagnosis and to treat them radically as
soon as possible.
One of the more interesting facets of the
microadenoma story is the syndrome of galac-
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torrhea and amenorrhea. Historically, three
types of galactorrhea and amenorrhea have
been described, depending upon whether the syndrome appeared following delivery or spontaneously.
The group of interest here is the Forbes-Albright syndrome, which can have its onset either postpartally
or, more often, spontaneously. By definition, the sella
turcica is enlarged, and galactorrhea and amenorrhea
are permanent. The only difference between the
Forbes-Albright and the Del Castillo syndrome is the
normal sella, and here I think it is a matter of time.
These patients have microadenomas, but until one
studies the sella by polytomography, the sella may
appear normal. We now have eight of these
patients-three harbored macroadenomas and the
remainder, microadenomas. These, like the ACTHsecreting adenomas, have a greater liability than the
usual chromophobe adenoma to become invasive.
For some reason, unlike the growth hormonesecreting adenomas or acromegaly, tumors that
secrete prolactin and tumors that secrete ACTH are
inherently bad actors; that is, they have a relatively
high risk of becoming malignant as judged by invasive behavior.
Excluding one patient with an intrasellar
abscess, we have had no operative deaths, and this is
a significant advantage of the technique. We divided the morbidity into major and minor, the major including pneumonitis and rhinorrhea . If we think
that the patient might be developing rhinorrhea, we
treat vigorously in the first five postoperative days; I
am certain that we are overtreating and unnecessarily
treating a number of patients. We insert a lumbar
subarachnoid drain, start Diamox®, and elevate the
head; and our rhinorrhea rate falls very rapidly. Two
patients had transient cranial nerve palsies due to
vigorous use of a curette against the wall of an
already compressed cavernous sinus. One patient had
a postoperative hematoma within the tumor capsule.
This was recognized within four hours, and the
patient was returned to the operating room, where it
was removed with no consequences. Five patients
had diabetes insipid us persisting longer than a month
and four patients had transient diabetes insipidus. An
aseptic meningeal reaction from blood in the CSF,
sinusitis, nose bleed, one corneal abrasion, and
urinary tract infections represented minor complications . In no patient who had either normal or
impaired vision prior to operation was vision made
worse; this makes it a very attractive procedure,
because even with the very best results from the
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transfrontal technique, vision was made worse in an
occasional patient.
The transsphenoidal technique is the procedure
of choice under the following circumstances.
l. Sphenoidal extension;
2. Modest suprasellar extension without lateral
extension: We can handle the direct upward
suprasellar extension. In the last 18 months, I
have operated on 40 pituitary tumors, only
one of which was· done by craniotomy. There
was a suprasellar extension that went laterally
into one frontal lobe, and you simply cannot
turn the corner going through the sphenoid
sinus. Consequently, this patient was done
transfrontally.
3. The patient with paracentral, bitemporal
scotomas: The neuro-ophthalmologist will
assure you that this patient has either a prefixed chiasm or a retrochiasmal nodule.
This presents a difficult problem for the
neurosurgeon operating transfrontally, because the optic nerves are hugging the
tuberculum and there is no room to work
between the optic nerves. This is, in my opinion, an indication, unless there is some contraindication, to the transphenoidal route.
4. The microadenoma (mentioned earlier);
5. Spontaneous rhinorrhea in association with a
pituitary tumor;
6. Pituitary apoplexy : A low morbidity
procedure accomplishes what you want to accomplish very quickly, and since these
patients are often ill and need rapid decompression, I think it is clearly the procedure of
choice for pituitary apoplexy.
7. The patient who is old or debilitated for
whatever reason, or if you simply want to do
a biopsy.
Which tumors should be approached by the
transfrontal technique? Again , this is my own prejudice. The massive suprasellar extension is a huge
mass of intracranial tumor, and what is happening
within and immediately above the sella is really not
the important part of the tumor. I have discussed the
tumor with lateral extension. Perhaps tumors with
massive suprasellar and sphenoidal extensions should
be removed sequentially by both routes . The one contraindication to any major procedure is unequivocal
cavernous sinus invasion. Extraocular motor palsies
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alone are not an indication of invasion. As pointed
out by Sir Geoffrey Jefferson, a fixed sensory loss is
the one clinical sign of cavernous sinus invasion.
In summary, the one thing that is new in
the management of pituitary tumors is the
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transsphenoidal technique. Obviously, there still
remains a place for transfrontal craniotomy and
cryosurgery, but I predict that an increasing number
of pituitary tumors will be done by the
transsphenoidal technique.

Advances 1n the Treatment of
Patients with Benign Brain Tumors*
HAROLD F. YOUNG, M.D.

Associate Professor of Neurosurgery, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University, Richmond

Introduction. Since the Stoneburner Lecturer for
this year, Dr. Thomas Langfitt, is Professor and
Chairman at the hospital of the University of Pennsylvania, it would only be proper to recall at least one
of the important lessons taught by Dr. Francis Grant,
Dr. Langfitt's predecessor at the University of Pennsylvania. One of Dr. Grant's most remembered dictums was that when a benign brain tumor is encountered, the best surgical team the clinic can
assemble should be put to work on it (!). This is a
valuable concept in the treatment of benign brain
tumors. It is of paramount i.mportance to protect the
brain, to preserve neurological function, to restore
neurological function which has been lost, and to
remove the tumor completely if possible. Ample
statistics reveal a 20% recurrence rate in operated
benign central nervous system tumors, a rate largely
related to incomplete removal at the first operation
(2).
What are the recent advances which will ensure a
better fate for the brain tumor patient? First is the
diagnosis of the degree, if any, of increased intracranial pressure (ICP) before surgery; second is the
meticulous management of anesthesia at surgery; and
third is the use of the operating microscope with the
associated microneurosurgical instrumentation to
provide magnification surgery.
Intracranial Pressure. The recognition of increased intracranial pressure is important not only in
benign brain tumors but all brain tumors which
*Presented by Dr. Young at the 27th Annual Stoneburner
Lecture Series, February 8, 1974, at the Medical College of
Virginia, Richmond.
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manifest increased intracranial pressure by headache,
altered states of consciousness, and the finding of
papilledema. All brain tumor patients treated at
MCV have ICP monitoring for three-to-five days
before surgery, during surgery, and for at least three
days following surgery with a subarachnoid screw (3).
Figure l is a recording of intracranial pressure
demonstrating increased intracranial pressure as the
patient is being monitored before and during steroid
treatment prior to surgery.
If the baseline ICP is elevated above 40 mm Hg
(normal less than 11 mm Hg), there will usually be
plateau waves-a transient marked increase in ICP
up to 60 Hg. With the rise in ICP or at the time of a
plateau wave, there may be a decrease in the level of
consciousness, hypoventilation, and an increase in Paco .
The patient may then be aroused by severe headache~,
or by an examiner, and may then hyperventilate,
lowering the Paco , relieving the headache, and returning intracrani~I pressure to the baseline.
We have found, upon establishing the baseline
ICP, that there is usually no rapid reduction of ICP in
the first 24 hours of steroid therapy even though
clinical improvement is seen during the same period.
We have often observed a decrease in the number of
plateau or Lundberg waves occurring in the first
24-36 hours of steroid treatment. Early clinical improvement in the patient's condition, not associated
with a lowering of mean ICP, may reflect a direct
effect of steroids on the brain or improvement in
cerebral blood flow as brain edema is reduced.
Because ICP is usually reduced only after at least
24-36 hours of steroids, all of our patients are
prepar,ed for brain tumor surgery with three-to-five
MCV QUARTERLY 10(4): 196-199, 1974
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days of steroids. During this long period of time, in
which steroids may be necessary to reduce ICP, effect
membrane stabilization and capillary integrity, they
also may have a beneficial effect on other subcellular
organelles such as lysosomes, which appear better
preserved when the patient has been well prepared
with steroids. Without steroids, under stress of
trauma, breakdown of lysosomes results in formation
of lipofuscin bodies and the release not only of acid
phosphatases, but of other hydrolytic enzymes as well
(4). Experimental evidence also reveals a decrease in
the severity of the traumatized brain when treated
with steroids (5); thus, we use ICP monitoring and
long-term steroid administration prior to surgery to
reduce ICP and to protect the brain from any trauma
that may occur during surgery.
Anesthesia. The next important aspect of the
management of patients with benign brain tumors is
induction of anesthesia. This is a most critical time
for the patient. Even preoperative sedation can cause
hypoventilation, blood gas changes, and alterations
in intracranial pressure between the time the patient
leaves the floor and the time he arrives in the
operating room. All brain tumor patients undergoing
surgery have intracranial pressure subarachnoid
monitoring not only preoperatively but during the
induction of anesthesia as well. Likewise, an arterial
line from the patient's radial artery is connected to a
4 channel Grass recorder, and end-expiratory C0 2 is
measured on a capnograph. By this technique we
have been able to confirm that there are many times
during the induction of anesthesia when a change in
ICP may occur (6). A rise in ICP may be hazardous
for the patient if increased intracranial pressure is
present at the induction of anesthesia. It is best to
have knowledge of the intracranial pressure prior to
the induction of anesthesia as hyperventilation or intravenous mannitol may be needed to reduce intracranial pressure. For instance, while halothane is
not a dangerous anesthetic, increasing its concentration quickly increases intracranial pressure. Figure 2
shows the reduction of ICP when intravenous pentothal is administered. This is in agreement with
Shapiro's recent report showing that thiopental
sodium, or pentobarbital, will reduce intracranial
pressure (7). Ethane is an agent useful in lowering intracranial pressure unless increased to a concentration of 4% or more. lntracranial pressure monitoring
reveals a balanced barbiturate anesthetic to be a
valuable anesthetic technique in brain tumor surgery.
At the time of intubation, there is usually a brief
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!NTRACRANIAL PRESSURE WITH

STEROID AOMINSTRATIDN
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Fig. 1-lntracranial pressure recording in mm Hg during 5 days of
steroid (Decadron® 4 mg Im q6h} treatment. On day I and 2
baseline ICP runs between 30-40 mm Hg with plateau waves up to
60 mm Hg. Plateau waves disappear on day 3 but baseline ICP is
only in normal range on the fifth day of treatment.

increase in intracranial pressure associated with a
small change in arterial blood pressure (Fig. 2). A
short period of straining on the endotracheal tube
will likewise produce a rise in ICP, and prolonged
straining or "bucking" must not be allowed.
After the induction of anesthesia, the surgeon
must carefully position the patient's head for his surgical advantage without turning the head so severely
that a major blood vessel to or from the head is
occluded; this is often overlooked in preparing the
patient for surgery. Care must be taken not to
obstruct venous drainage from the head as this will
certainly increase ICP.
INTRACRANIAL PRESSURE AND BLOOD PRESSURE
CHANGES AT ANESTHESIA INDUCTION
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Fig. 2-(Top Tracing) Pentothal lowering ICP within l minute of
administration; 50 mg pentothal produced a slight decrease in ICP
while 350 mg produced a marked decrease in ICP. (Bottom Tracing) Rise in ICP to almost 60 mm Hg during intubation.
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Following the induction, both the surgeon and
the anesthesiologist must also focus on ventilation of
the patient. Figure 3 is the ICP recording of an operation on the posterior fossa where spontaneous
respiration is generally used since it is a safeguard
against undue trauma or traction of the bq1instem .
Spontaneous respiration produced a prompt rise in
intracranial pressure and the patient was then placed
on a respirator to control ventilation and reduce ICP.
In order to operate on an adult patient, intracranial
pressure is maintained in a safe range witjl ventilation
controlled at the rate of 12 respirations/ min and a
tidal volume of 900 cc with each respiration . Unfortunately, when the surgeon is operating he may,
nevertheless, reach a point where he is about to open
the dura only to find it very tight. If the surgeon
demands that the anesthetist hyperventilate the
patient, an over reaction by the anesthetist of rapid
hand ventilation may result in exchange of a small
tidal volume too rapidly for sufficient venous return
and intracranial pressure may not be lowered but
may actually be increased. The induction of
anesthesia must be attended by the neurosurgeon as
well as the anesthetist. This is one of the most important aspects of the operation, errors in management
of the anesthetic resulting in intracranial pressure
changes could lead to a tragic result from the operation.
Magnification Surgery. One of the reasons for
emphasizing control of intracranial pressure and the
induction of anesthesia is that it is important, in the
technique of operating on a brain tumor using an
operating microscope, to have as much ttxposure as
possible often beneath the brain or deep within the
SPONTANEOUS AND ASSISTED
VENTILATION IN SURGERY
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Fig. 3-Intracranial pressure recording during posterior fossa surgery demonstrating repeated elevation of ICP whenever the patient
is allowed to breath spontaneously. This elevation of ICP is corrected by assisting respiration (Top Tracing).

Fig. 4-Ceiling-mounted operating microscope in the
neurosurgical operating room at the Medical College of Virginia.
Focusing is accomplished by foot control pedal not shown in
figure .

brain without retracting the brain. Careful attention
to the small metabolic parameters discussed above
afford a much better opportunity to operate on the
brain under relaxed conditions. Brain retractors
should be used to protect the brain, not to retract the
brain, and the tumor must be removed from the
brain, not the brain from the tumor. The operating
microscope has changed our approach not only to intracranial vascular surgery, where it is absolutely
necessary, but also to benign brain tumor surgery as
well. Presently the only type of tumors not requiring
use of a microscope are malignant gliomas of the
cerebral hemispheres.
At MCV a ceiling-mounted microscope allows
the surgeon and one assistant or resident to see and
become involved in the operation (Fig. 4). The best
place to install a ceiling-mounted microscope is in the
center of the operating room. Many surgeons prefer
the floor-mounted movable microscope, finding it
easier to move the microscope to the patient than to
move the patient to the fixed microscope. The
limitations of the microscope earlier in our ex-
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perience included the fact that it made resident
teaching difficult and did not allow the scrub nurse or
the anesthesiologist the opportunity to view the surgery. A video tape camera can be attached to the
operating microscope allowing both the scrub nurse
and the anesthesiologist to view the surgery and also
the televising of the surgery to any location in the
hospital, providing greater flexibility of the microscope as a teaching instrument.
The important lessons in developing excellent
microsurgery techniques are learned in the
microneurosurgical laboratory. An extended period
of time must be spent in the laboratory learning how
to handle and drape the microscope as well as to
learn microneurosurgical instrumentation and
techniques. The MCV division of Neurosurgery has
such a laboratory, One should borrow neither the
ophthalmologists' nor the otolaryngologists' microscope for an occasional neurosurgical operation
nor purchase a set of a famous neurosurgeon's instruments and expect to immediately perform magnification neurosurgery.
With the proper use of the microscope, it is
possible to approach any area in or near the brain to
safely remove tumors while preserving vital structure.
For instance, the microscope has been the primary
reason for the renewed interest in the transsphenoidal
approach to pituitary surgery. The small secreting
tumors of the pituitary causing acromegaly can now
be removed while preserving the pituitary gland (8).
Summary. Reliable ICP measurement allows an
exact quantitation and management of intracranial
pressure. This precise assessment of ICP is a valuable
adjunct in the management of anesthesia for brain
tumor patients. The proper combination of ICP and
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anesthesia management enables the surgeon to use
the operating microscope to approach previously inaccessible areas of the brain and to perform
meticulous surgery with a better prognosis for the
brain tumor patient.
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Advances 1n the Management of Patients
with Malignant Brain Tumors*
CHARLES B. WILSON, M.D.

Professor and Chairman, Department of Neurosurgery,
University of California, San Francisco

In describing what is new in the management of
malignant brain tumors, I shall confine myself largely
to chemotherapy and shall outline what we think is
important based on our own experience, what we
have achieved with single and multiple agents, and
where we are going. We have just reviewed our fiveyear experience and find that chemotherapy, perhaps,
is the only thing that is new.
The development of drugs since 1943 has been
escalating at a fantastic rate. Today, we can provide
the chemotherapist with a wide array of drugs from
which to choose.
Several neoplastic diseases are now recognized
as being highly responsive to chemotherapy and the
list is growing. The first to be recognized was
childhood lymphocytic leukemia, then choriocarcinoma, and now testicular carcinoma and Wilm's
tumor.
The first consideration for effective brain tumor
chemotherapy, as we see it, is that the agent must
have optimum lipid solubility or a special transport
system. We are convinced that it must penetrate the
normal brain to be truly effective, and I shall indicate
our reasoning below.
One must achieve an adequate drug level in
brain adjacent to the tumor with minimal or no
neural toxicity, and the drug must be given frequently
enough to produce maximal DNA damage with insufficient time for repair. At the present time, we are
studying the rate of DNA damage and repair in a
search for combinations of drugs that will give less

* This is an edited transcription of a lecture presented by Dr.
Wilson at the 27th Annual Stoneburner Lecture Series, February 8,
1974, at the Medical College of Virginia, Richmond.
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than added toxicity and, at the same time, will
produce synergistic antitumor effects.
A water soluble compound is excluded by the intact blood-brain barrier and, administered intravenously, the drug attains a high concentration
only in the leaky, central portion of the tumor. As the
drug moves toward ventricular and subarachnoid
cerebral spinal fluid (CSF), the concentration falls
very rapidly, so that the active periphery of the tumor
is exposed to low concentrations of its drug and for a
brief time orily. If one gives a water-soluble drug in
the CSF, however, it moves quickly across the ependyma into adjacent brain . It does not exit from the
normal brain but diffuses through brain ipto tumor.
This would be a reasonable way, then, to give a
water-soluble drug.
On the other hand, if one uses a lipid-soluble
agent, for example, the nitrosoureas, it crosses
capillaries in the normal brain. Obviously, it crosses
the tumor's leaky capillaries, so that one has equal
drug concentrations in brain adjacent to tumor and
in tumor. If one injects a lipid-soluble drug into the
ventricle, it crosses the ependyma, instantly goes out
through the capillaries of the normal brain, and none
of it ever reaches the tumor, unless it happens to be
very close. It would be irrational to use a lipid-soluble
drug intrathecally. With lipid-soluble compounds,
concentration in the tumor is the same as concentration in the brain. We believe that this is important
both froin the theoretical standpoint and from our
own experience.
Our group is interested in developing effective
drugs and drug schedules in the laboratory and in
bringing these into clinical trials. We started out with
a rat glioma; now we have two rat gliomas and three
MCV QUARTERLY 10(4): 200-204, 1974
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mouse gliomas, which we use for drug screening. In
the past, we have used reservoirs in pups for intrathecal administration. We can perform intrathecal
injections in the rat, so that it provides a model for
therapy, either by continuous intra-arterial infusion
or by intrathecal injection. We are not limited by the
route of administration. It turns out that the models
have been extremely useful, not. only for screening
promising compounds but also for working out drug
schedules and routes for administration.
The kinetics of brain tumors are most important.
We have studied animal tumors and have completed
studies of human tumors in vivo. To summarize what
we know about a glioblastoma at the present time, we
have shown that in a glioblastoma, approximately
30% of viable cells are actively dividing and the other
70% of the cells are nondividing (nonproliferating).
The cell cycle, that is, the length of time it takes a
glioblastoma cell to go from one mitosis to two cells
at the next mitosis, is somewhere in the range of 21/2-3
days. Were it not for a very high rate of cell loss, the
volume of a glioblastoma would double in approximately one week. This is unrealistic on the basis
of clinical observation. We know that the period of
time required for the glioblastoma cell to synthesize
its DNA is about 9-10 hours and, interestingly
enough, it takes an astrocytoma the same period of
time.
In our studies, we have used radioactive
thymidine, labelled either with tritium or with 14C.
We have documented the intense proliferation seen in
blood vessels within a glioblastoma. In all probability, the limiting factor in the growth rate of a
glioblastoma is the rate at which the blood vessels can
proliferate, because there is good reason to believe
that the capillary endothelium cannot divide as rap- .
idly as tumor cells. In brain adjacent tumor, in
the absence of tumor cells, because of tumor
angiogenesis factor, blood vessels proliferate in advance of invasive tumor.
The brain presents a particular problem. After
treatment with an effective chemotherapeutic agent, a
dead cell takes up approximately twice as much room
as living cell. The result is an increment of edema or
swelling of tumor cells and an increase in volume.
This increased volume can be detrimental because of
the effects of an increase in intracranial pressure.
Dead cells must be removed; although these cells are
now nonviable, they are still present and therefore act
as a mass. We have just completed studies on deadcell removal and have shown that when one puts
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tagged, lethally irradiated cells in brain, muscle, and
subcutaneously, brain has a most inefficient, sluggish
means of dead-cell disposal. We are convinced, both
from pathological studies as well as our own observations, that the brain is relatively inefficient in
removing dead cells as opposed to other solid organs.
At this period, we often have to use steroids to combat increased intracranial pressure and the question
arises as to what steroids do to tumors?
Methyl prednisolone or any of the glucocorticoids will increase the survival of tumor-bearing
animals that receive the steroids. Thus, you can increase the survival of a rat bearing a glioma by giving steroids. If one has a control group and a group
treated with methyl prednisolone, and they are killed
at the same time (in this instance on the 21st day) one
finds that the tumors in the control animals vary
pretty widely but •have a mean weight of 157 mg,
whereas the tumors of the animals receiving steroids
are much smaller with a mean weight of 36 mg. One
can explain this difference in two ways-steroids kill
tumor cells and steroids slow down the rate of cell
proliferation. We now have evidence that the latter is
true. There is no direct oncolytic effect on glial
tumors, but the steroid simply puts certain
proliferating cells into a nonproliferating state, and it
also increases the period of time necessary for a cell
to divide, that is, the cell cycle time. This became very
important when we checked our own clinical
statistics. Were we confusing ourselves in judging
drugs by the concomitant use of steroids? To answer
the question, we took consecutive patients. One
group of patients never received steroids. With an approximately equal number of patients in both groups,
we determined how many were chemotherapy
responders, probable responders and nonresponders.
The concomitant use of steroids did not change the
frequency of response to chemotherapy. We have
concluded that steroids have one major effect in the
brain tumor patient, that of reducing cerebral edema.
To date, we have no clinical evidence that they have
any effect on tumor cells.
The material that I intend to present is based on
a particular group of patients. These are patients who
either have tumors recurrent following surgery and
radiation therapy or in whom the diagnosis of a
malignant tumor could be m ade without a ny
reasonable doubt and whom we elect to treat by
chemotherapy rather than by radiation therapy. In
the latter group, we do not insist upon a tissue
diagnosis, feeling that the price of obtaining a tissue
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diagnosis is to justify the biopsy of a glioblastoma or
a brain stem glioma. For reasons that I shall point
out, this is more often the case.
Consequently, patients who are eligible for our
Phase II trials are those either with recurrent tumors
or with primary tumors who are considered candidates for primary chemotherapy without surgical
verification. In addition, we treat a small number of
patients with metastatic tumors. A phase II trial asks
one question: Is the drug effective, that is, does this
drug have some activity against the tumor? It asks
neither what the cure rate is nor for how long. A
phase II study is designed solely for searching out and
identifying effective drugs. For a patient to be eligible
for this kind of study, he must first be ineligible for
other studies in our program. Second, with a
pathological diagnosis or an unequivocal radiographic and clinical picture, . the patient is deteriorating neurologically. Third, if radiotherapy
has been given, it must have been completed at least
three months prior to chemotherapy. Dead cells hang
around after the completion of radiotherapy, and late
improvement can occur following radiotherapy. As a
matter of fact, since we have instituted this rule, we
have actually confirmed delayed improvement up to
three months after radiotherapy. Finally, the patient
is expected to live at least two months, and we are
sometimes wrong on that estimate, but the patient, or
more often his family, understands the complications
of chemotherapy. Parenthetically, I can say that we
have lost approximately l % of our patients as a direct
result of complications of chemotherapy; our morbidity has been higher. Mortality has remained low
because we have means of rescuing the patient who
gets thrombocytopenia or leukopenia.
Thirty-four patients were not treated because: l)
we found no evidence of tumor regrowth, 2) we
thought that they would live less than two months, 3)
they declined treatment after understanding it, or 4)
further surgery was elected. In the latter category, a
benign fourth ventricle cyst was referred to us as a
recurrent brain stem glioma, and we sent the patient
back with diagnostic studies to the referring
neurosurgeon who removed the cyst. Recently, I
removed a nerve sheath tumor of the tenth nerve
which had been misdiagnosed as a brain stem glioma
and, after radiation therapy, was sent to us for
chemotherapy. We have seen a ·variety of misdiagnosed lesions, emphasizing the need for careful study.
In one patient, we thought radiotherapy was the
treatment of choice.
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To judge the effect of chemotherapy, we use two
criteria. We have a third which will probably be
added-the EEG (which came as a complete surprise
to me). At first, I would not allow our electroencephalographer to charge our patients, because I
was convinced that EEG would be valueless, but it
did just about as well as a scan in predicting whether
a patient was better or worse. We, like others, will be
looking to the EMI scanner for a fourth criterion.
The two criteria on which our data are based are the
clinical status and the brain scan. A patient classed as
a responder is better clinically and his brain scan is
better. A patient is designated a probable responder if
clinical status is: l) improved and the brain scan is the
same, 2) if the clinical status is the same and the brain
scan is better, or 3) if both of them remain the same
for at least three months in the case of medulloblastomas and glioblastomas and six months
for more benign tumors. A nonresponder deteriorates as judged by clinical status and brain scan.
A certain number of patients in our series were
nonevaluable. We determined, in retrospect, that
patients surviving for less than two months after
beginning treatment were not evaluable-again,
because of the slow removal of dead cells. Approximately 15% of all responders were considered
failures when they returned for their second course of
therapy. If a patient receiving a course of
chemotherapy is obviously worse six weeks later, it
does not mean that the drug is ineffective, because
among those patients who eventually turn out to be
unequivocable responders, 15% have had an initial
deterioration in brain scan and clinical condition.
Several patients were nonevaluable because, in the
beginning, we were inexperienced. In some, the
neurological condition was not clearly deteriorating
immediately prior to treatment; others failed to complete one full course; and on five patients, we were
unable to obtain an adequate follow-up.
What can we expect in using single drugs? With
BCNU (still the best single drug used to date), 27 of
our 57 patients showed a response, a rate of 47% over
a mean duration of nine months, and this a population of recurrent tumors. CCNU has a response rate
of 44% but for a shorter mean duration. Procarbazine, also a powerful drug with a 52% response
rate, has a mean duration of six months. We are unable to give an explanation for the fact that when we
combine BCNU and vincristine (which should be a
good combination because vincristine is not toxic to
the bone marrow), we get a response rate of only 45%
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over four months. Although BCNU and CCNU are
virtually identical and both are highly lipid soluble,
BCNU seems to have a clear advantage. Procarbazine ·
is not lipid soluble, but it does proceed rapidly, in
high concentration, into CXF. The three most effective single agents, thus, have in common bone
marrow toxicity and very rapid entry into brain and
into CSF.
What of the patient who receives a first drug
and, whether with or without response, then proceeds
with a second drug? A response to a second drug is
very small, probably for two reasons-one, a possible
cross resistance and two, by the time of proceeding to
a second drug, the patient is usually in poor
condition.
What can be said of tumor types as related to
specific drugs? With malignant gliomas and
astrocytomas or glioblastomas, the response is
similar with all of the three most effective drugs. For
ependymomas, BCNU is extremely good, one of our
patients responding to BCNU as the second drug administered. The other tumor-specific chemotherapy,
which I shall go into later, is the combination of
procarbazine, CCNU, and vincristine that seems to
be highly effective for medulloblastomas.
As must be well known, BCNU is given intravenously on various schedules; it is quite likely
that we do not use the optimal schedule. One of our
early patients, a quadriplegic with an ependymoma,
had a fantastic response over several months to
BCNU, but ultimately could not receive any more
due to the development of cumulative bone marrow
toxicity. One patient with a malignant astrocytoma,
having been treated with BCNU for two years, shows
no evidence of tumor regrowth after two and one-half
years off treatment. One young boy, who had a
recurrent ependymoma of the fourth ventricle with
supratentorial metastases, tumor cells in his CSF,
and recurrent tumor in his posterior fossa, was
treated with BCNU for two and one-half years; he is
attending college now with no evidence of recurrent
disease after two years off treatment.
The Brain Tumor Study Group has studied
BCNU in a phase III trial, taking patients who had
had a major craniotomy and removal of a supratentorial glioblastoma. Postoperatively, these patients
were not dependent upon steroids and they randomized within three weeks of operation; thus, this is
a select group of patients treated in the early
postoperative period. Patients who received no
further treatment had a median survival of 15
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weeks-a little less than four months, which seems to
be a little on the low side. Those patients who received only BCNU postoperatively had a median survival of 21 weeks; those who received irradiation
therapy had a median survival of 30 weeks; and those
receiving BCNU plus irradiation had a median survival of 40 weeks. How do we interpret this? Irradiation and BCNU combined are better than either
alone and better than no further treatment after surgery as well. Of the various forms of adjuvant therapy
reported for glioblastomas, the most effective is
BCNU and irradiation combined following major
tumor removal. At the time of this study, about four
years ago, BCNU was used because it had been
shown to be an active drug in phase II trials.
One of the people in our laboratory became an
expert at removing rat gliomas, and we evaluated adjuvant chemotherapy and surgery, using a rat brain
tumor model. We asked: Are we giving BCNU at the
right time? Should it be given before operation, with
the operation, or afterwards? We tried various combinations of BCNU and surgery and in one group, we
even added 5-FU to obtain early proliferating
postoperative cells. The study showed that there was
no combination of surgery and BCNU that was as
beneficial as BCNU alone. I could not believe it and
we repeated the experiments four times. The experiments defied my prejudice and the basic laws of
cell kinetics, and the results have now been submitted
for publication. I do not believe, however, that on
this basis, neurosurgeons will stop removing
glioblastomas, but we did feel encouraged to treat a
few human glioblastomas, diagnosed angiographically without histological verification. Of the patients treated in this way, only two harbored primary reticulum cell sarcomas that we called
glioblastomas-not a large error.
Procarbazine is a monoamine oxidase inhibitor
and patients under treatment, therefore, cannot eat
ripe cheese or take certain drugs. One patient, who
showed excellent results by brain scan, became
irreversibly psychotic, so it is not a perfect drug, but
it does move rapidly into the CSF. In one of our first
patients, with a recurrent medulloblastoma and a
total spinal block, procarbazine alone melted away
the mass. Though active against medulloblastomas,
procarbazine alone is not as active as a more recent
drug combination to be mentioned below. Its activity
against malignant gliomas is similar to BCNU.
Single drug therapy for solid tumors is rarely
curative in animal ·or human systems after the tumor
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reaches a clinical size. Those people interested in
solid tumors, therefore, are looking to combination
chemotherapy, using drugs that have qualitatively
different toxicity and complimentary mechanisms of
action to prevent the emergence of resistance clones,
and are combining agents that act on cycling versus
noncycling (nonproliferating) cells.
Our first multiple drug protocol involved three
drugs: CCNU, which we knew was active and could
be given by mouth; vincristine, which was active and
did not add toxicity to the bone marrow; and procarbazine, which we thought was an excellent drug. The
course was given on a 28-day cycle: CCNU on day 1,
procarbazine for the first 14 days, and vincristine
twice (days 1 and 8). We obtained a response rate of
57% (I cannot give the median duration, but it has
produced some of the most dramatic responses we
have seen with medulloblastomas.). We are now persuaded for the first time, that we have something safe
enough and effective enough to justify designing a
study of combining chemotherapy with radiotherapy
for the immediate treatment of verified medulloblastomas. Our response rate here has been
well over 75%, but the patients do develop chronic
bone marrow toxicity. For example, a little girl who
came in with papilledema and huge subfrontal
metastases had a normal brain scan two months ago,
after receiving procarbazine, CCNU, and vincristine,
but due to chronically depressed bone marrow, we
are unable to give her more drug and she is experiencing a recurrence.
We tried the combination of Cytoxan®
(cyclophosphamide), CCNU, and vincristine. We
saw few responses and concluded that this is not an
effective combination.
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What are the approaches to more effective
chemotherapy? We are convinced that drug combinations are the wave of the future. Simultaneously,
we are trying to identify new effective single drugs
and effective combinations of single drugs. We are
now actually putting into practice schedules based on
kinetic information, that is, cell cycle and number or
percentage of proliferating cells. It may be possible to
convert tumor cells that are nonproliferating into a
proliferating state in which they are more susceptible
to drugs specifically damaging to proliferating cells.
Possibly, we can convert some normal cells, such
as gut and bone marrow, from their normal
proliferating state to a noncycling compartment, particularly bone marrow, so that it will not be
devastated by the drugs we use. We do not have a
single drug today that is specific for cancer cells and
are always on a tight wire between poisoning the host
and poisoning the cancer.
We hear a great deal about enhancing immune
mechanisms. In the one reported study, patients who
were immunized did no better than those who were
not. There are some very promising things on the
horizon, but at the moment, I see no immediate role
for immunotherapy. The successful acceleration of
dead cell disposal, in which we are extremely interested, will have some practical application.
In summary, our studies have identified three
agents individually active against a variety of brain
tumors. Procarbazine belongs in another pharmacological group, but BCNU and CCNU are
similar. Combination chemotherapy holds great
promise for brain tumor chemotherapy, and one of
the two combinations evaluated by us is highly effective against medulloblastomas.

Practical Anticonvulsant Pharmacokinetics*
R. B. DA YID, M.D.
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Health Sciences Division of Virginia Commonwealth University, Richmond

L. K. GARRETTSON, M.D. ·

Associate Professor of Pediatrics and Pharmacy-Pharmaceutics,
Medical College of Virginia, Health Sciences Division of
Virginia Commonwealth University, Richmond

Pharmacokinetic Considerations. Pharmacokinetics is that area of pharmacology concerned
with the absorption, distribution, metabolism, and
elimination of drugs. The processes by which absorption, distribution, and elimination take place are
referred to as unit processes. These occur independently and concurrently, and involve such activities as absorption into the blood, elimination from
the blood, distribution between the blood and tissue,
inactivation in tissues, and finally, elimination from
the blood. Drug handling by the body can be
characterized by the rate for each step or, more often,
the rate of all processes. Classification of observed
kinetics for these rate processes includes first-order,
zero-order, and capacity-limited kinetics. In the
description of these processes, we will use total body
elimination as the rnodel, as this is the way most data
are handled clinically (1 ).
The rate of first-order or exponential drug
elimination is proportionate solely to the amount of
drug present. The half-life is constant regardless of
the quantity present. Thus, if the dosage is doubled,
the half-life ~ill remain the same.

* Presented by Dr. David at the 27th Annual Stoneburner
Lecture Series, February 8, 1974, at the Medical College of
Virginia, Richmond.
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Zeto-order kinetics is the term used to describe
processes where rates are constant per unit time; the
time required to rid the body of one-half the drug is
prolonged by increasing the body load. It is implied
that the rate process is limited, and the rate of
elimination is fixed.
Capacity-limited kinetics describe a situation of
a rate process being variable and between the limiting
situations of first and zero-order. As the number of
drug molecules approximates the number of
metabolic sites, for example, special mathematical
processes must be employed to describe the
responses. As drug ievels rise: the rate approaches the
zero-order rate (constant amount eliminated/ time)
and as levels fall, first-order rates are approximated.
If we consider the situation of drug overdose or
intoxication, it may help to clarify these different
kinetic patterns. If zero kinetics are operative as in
alcohol, the patient will rid himself of the same
number of milligrams each hour regardless of serum
level. At high levels in the body, this constant amount
is a very small percent of body load and the rate of
decline of serum concentratiop is slow indeed. If firstorder kinetics attain, as with phenobarbital, the total
body load in the intoxicated patient will decline to
one-half in the same time as the amount in the patient
with a therapeutic amount. The situation of sqtura-

205

206

DA YID, GARRETTSON: PRACTICAL ANTICONVULSANT PHARMA CO KINETICS

tion kinetics is an intermediate between the two. An
understanding of these principles is important mainly
for preventing intoxication, for efficient alteration of
dosage, and for unqerstanding individual variations.
While the determination of rate constants is important, other parameters are of concern. Absorption
parameters include both the rate of absorption and
the bioavailability or percentage of the drug absorbed
which reaches the active sites in the body. Distribution parameters include not only the rate of distribution but also the volume of distribution or extent to
which the drug is found outside the blood; this is
affected by protein binding. Protein binding may be
affected by disease states and other drugs.
The pharrnacologic effect on the desired organ
or organ system will be dependent upon the amount
of time in the body, the time exposed to the target
organ, and the specific properties of the drug used.
The occurrence of side effects is dependent upon
similar considerations.
There are many patient variables such as individual physiology, pathology, and genetic
characteristics, as well as developmental and environmental factors which effect drug response. A
drug serum assay (drug level determination) is but a
small part of the data necessary to make an intelligent
judgment with regard to m~ximizing the desired
effect in therapy. Serum assay determines only the
quantity in the serum and basic assumptions must be
made in regard to the organ or organ system where
the drug is a'ctive. Many factors affect the
relationship between serum concentration and drug
effect. An understanding of pharmacokinetic principles will result in less trial-and-error pharmacotherapy and more frequent consideration of important variables. For example, if the physician, as
his goal in treating the seizure patient, has established
that a patient should have no subsequent seizures,
then he will, with a basic understanding, be able to
prevent some of the seizures which occur during the
start-up and dosage-adjustment phases of drug
therapy; he may also avoid intoxication.
Clinical Considerations. The availability of drug
assays and pharmacokinetic data has already provided some useful information for the clinician (2).
This has increased our knowledge in four areas:
the initiation of therapy, dosage regimens, routes
of administration, and adjustment of dosage for
the four basic anticonvulsants-phenobarbital,
diphenylhydantoin (Dilantin®), primidone (Mysoline®), and ethosuximide (Zarontin®). These are

the most commonly used agents, and there are,
consequently, more pharmacokinetic data regarding
them.
Initiation of Therapy. With respect to the initiation of dosage, there is a rule of thumb that can be
helpful: If a maintenance dosage regimen is used to
initiate therapy, four times the half-life of the agent
will be required to achieve 90% of the ultimate serum
plateau. Since such a long time is required to reach
this plateau with some cjrugs, such as diphenylhydantoin, loading has been used, particularly to achieve
rapid therapeutic levels. Phenobarbital a nd
primidone, however, produce significant drowsiness,
so they are usually not "loaded." With ethosuximide, employed in the treatment of absence seizures,
loading doses are usually not used because of the
mild nature of the seizure being treated. Agents with
long half-lives, however, are, potentially, those with
which the initial dose should be larger than the
maintenance dose.
The usual starting dose for phenobarbital is 5
mg/ kg/ day in the child and about 1 mg/ kg/ day in
the adult. The half-life is 18-70 hours in a child (3)
and 55-120 hours in the adult (4). In general , the
younger the individual, the shorter the half-life.
The starting dose for diphenylhydantoin is 5-8
mg/ kg/ day for the child and 4- 6 mg/ kg/ day for the
adult. Once the therapeutic level is achieved, the apparent half-life is 8-12 hours. Loading of
diphenylhydantoin can be accomplished by giving
three times the maintenance dose in three divided
doses, three hours apart on the first day (5); the
second day, the usual maintenance dose is given.
Therapeutic levels are reached in 12 hours, and peak
serum levels are usually achieved on the third day.
Diphenylhydantoin may also be loaded intravenously
with accompanying electrocardiographic monitoring,
but not more than 50 mg/ minute should be given (6).
The initial dose ofprimidone administered is less
than the maintenance level because of the initial potent hypnotic side effects. Usually, a m aintenance
dose of 20 mg/ kg/ day is sought. Switching a patient
from phenobarbital to full maintenance primidone
usually can be accomplished without producing
sedative side effects. The half-life of primidone is
short-3-12 hours (7).
The starting dose of ethosuximide is 20 mg/ kg/
day. The half-life is a mean of 66 hours in a n adult
and 30 hours in a child.
Dosage Regimens. Because phenobarbital and
ethosuximide have long half-lives, once-daily ad-
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ministration can be employed, and because of
diphenylhydantoin's slow absorption, it also can be
given once daily. Primidone, having a relatively short
half-life, generally, should be given three times a day,
although some patients are well treated with twicedaily dosage. Ethosuximide may have a gastric irritant effect, so some clinicians employ it in a twicedaily regimen.
Routes of Administration. Ethosuximide and
primidone can be given only orally. Phenobarbital
can be given orally, intramuscularly or intravenously.
While diphenylhydantoin can be given orally or intravenously, intramuscular administration usually
fails to release sufficient diphenylhydantoin to the
blood, when given as the usual maintenance dose.
Doubling the maintenance dose when giving it intramuscularly is satisfactory, particularly when using
this route for short-term replacement of oral therapy,
as in surgery (8).
Adjustment of Dose. In adjusting the level of
medication, one should remember that phenobarbital
and ethosuximide are eliminated by first-order
kinetics and diphenylhydantoin, by capacity-limited
kinetics (9). Consequently, doubling the dose of
phenobarbital will double the blood level, as trebling
the dose will triple the blood level. When levels of
diphenylhydantoin are low, a similar relationship exists. At higher levels, in practice, apparently, above 10
µg / ml, the effect of capacity-limited kinetics is that
apparently relatively small dosage increments result in
greater serum level increases than is expected or
desired. Half increments are probably in order here.
The therapeutic ranges given for phenobarbital levels
are 10- 50 µg / ml, for prlmidone are 5-20 µg / ml, and
for ethosuximide are 40-80 µg/ml. The therapeutic
range for diphenylhydantoin is 6-20 µg / ml. Recent
work indicates that low serum levels are effective in
controlling seizures particularly in children.
Compliance. While our knowledge of pharmacokinetics has increased, one larger problem exists
in the area of compliance. Compliance is poor when
administration of the drug is too frequent, when multiple drugs are used on a different schedule, and when
the dosage form is unacceptable.
Three of the anticonvulsants mentioned can be
given as infrequently as once a day. This eliminates
the necessity for children to take these agents in
school. When multiple agents are given, it is relatively
easy to give all medications at one time.
Phenobarbital is available as an elixir, diphenylhydantoin and primidone, as suspensions. Where .i t is
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possible, the tablet form assures a more reliable
dosage intake. In the young child, all can be crushed
and given with jelly or other vehicles. Diphenylhydantoin comes as a chewable tablet, and
while it may produce more gingival hypertrophy than
the capsule, we continue to use it extensively.
Ethosuximide constitutes a rather special problem
being a liquid within a rather large gelatin capsule.
The capsule can be pricked by a pin and the liquid
mixed with juice or another vehicle by the pharmacist
or mother. One ingenious mother related that the
capsule can be frozen, then cut in half and given with
ice cream.
Memory crutches are useful. The most inexpensive is the traditional egg carton. Dial-a-packs are
also available and can be loaded by the patient with
his drug or drugs.
A new era is here. Practical pharmacokinetics,
skillfully utilized by the clinician, should aid immeasurably in producing seizure-free patients and in
reaching the goal quickly with fewer side effects.
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Introduction. Seizures can be due to a variety of
acute, subacute, or chronic diseases with different
etiologies. Clinically, they may manifest as focal or
generalized phenomena (Table 1). Whereas the majority of the patients suffering from partial seizures
are easily controlled with medications, in a small
number of patients treatment may fail. The failure
may be due to incorrect diagnosis or incorrect
therapy. The efficacy of medical treatment for seizure
disorder depends upon six factors: 1) dosage; 2) the
size of the patient; 3) drug interaction; 4) drug
specificity for the disease; 5) the nature of the disease
for which the drug is used; 6) the mode and frequency
of medication.
Dosage of Anticonvulsant. The dosage of anticonvulsant is very important (Table 2). ln our experience, the most common cause of failure in treatment of seizure disorders is undermedication. It is
also well known that the anticonvulsants in large
enough doses can act as convulsants. This is especially true for diphenylhydantoin, benzodiazepines,
and lidocaine. An important factor in dosage of drug
is patient reliability. Measurement of blood levels of
anticonvulsant can be helpful in this respect (Table 3).
Size of the Patient. The size of the patient
should be considered in dosage. Measurement accord-

* Presented by Dr. Hooshm a nd at the 27th Annu al
Stoneburner Lecture Series, February 7, 1974, at the Medical
College of Virginia, Richmond.
** This study was supported by a grant from Hoffman LaRoche Co.
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ing to body surface is safer and more accurate
(Table 2). As the child grows, there may be a need to
gradually increase the dose of anticonvulsants if
seizure control is pqor or if the serum level of the anticonvulsant starts to decline.
Drug Interaction. The relationship of multiple
drug therapy to its toxic effects on the brain is quite
complicated, and many forms of therapeutic failure
or toxicity can result.
Combination of Similar Drugs. Failure or toxicity
may be the result of a combination of pharmacologically similar drugs. Such a combination may
enhance the side effects of drowsiness and ataxia. The
patient may suffer from these side effects without attaining therapeutic levels of individual anticonvulsants in the blood. For example, a combination of
drugs such as phenobarbital and primidone may
result in severe ataxia and drowsiness while measurement of serum levels of phenobarbital and primidone
in such patients may show subtherapeutic levels.
The combination of the following pharmacologically similar drugs should be avoided: 1)
phenobarbital and primidone, mephobarbital
(Mebaral®), and metharbital (Gemonil®); 2) ethosuximide and methsuximide; 3) diphenylhydantoin
(DPl-1) and mephenytoin; 4) trimethadione and
paramethadione; 5) benzodiazepines (e.g., combination of diazepam , clonazepam (Clonapin®), chlordiazepoxide); 6) phenobarbital and ethanol; 7)
phenobarbital and benzodiazepines.
Combination of Inducers of Drug Metabolism.
This combination may result in less effective
MCV QUARTERLY 10(4): 208-219, 1974
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TABLE I
A Simple Classification of Seizure Disorders•
I. Focal {partial)

a. cortical
b. subcortical
c. both cortical and subcortical
2. Generalized
a. low threshold (e.g. drug withdrawal, toxic-metabolic,
benign febrile seizures)
b. secondary to focal

* Any of the above may be clinical or subclinical (EEG
manifestation).
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therapeutic doses of each drug in the blood, and less
effective control of seizures, despite toxic side effects.
Whereas the failure may be due to genetic, pharmacological or physiological factors which alter absorption metabolism or excretion of the drug, or the
failure may be due to compliance behavior of the
patient or to lack of drug specificity for the disease,
the clinician may add other anticonvulsants which
are inducers of drug metabolism and may result in
toxicity without control of seizures. The combination
may fail to control the seizures, but may result in side
effects of drowsiness (1) and/ or hyperactivity, also.
For example, diphenylhydantoin (DPH) at 5
mg/ kg/ day would result in a stable blood level of the
drug (2); however, an occasional patient on the same
dosage may represent marked blood accumulation of
the drug and toxicity (3), while others on the same
dosage may reveal very low drug levels and poor

TABLE 2
Dosage, Therapeutic Drug Levels, Indications, and Side Effects of Routinely Used Anticonvulsants
Average Daily Dose
(ED 50)

TD 50
{Toxicity)
(mg/ kg)

Safety
Range
(TD/ ED)

F, G, S

5 mg/ kg (0.3 g/ sqM)

20

4

F, G, P, C, S

I .5 mg/ kg (0.1 g/ sqM)

4.5

3

L, G

10 mg/ kg (0.6 g/ sqM)

140

p

20 mg/ kg (1.2 g/ sqM)

P, C

Skin Rash
Leukopenia

Hyperactivity

I0-20 µg/ ml

±

±

I0-50 µg/ ml

±

+++

I4

4-I2 µg/ ml

±

+

I50

IO

40-IOO µg/ mI

+

+

10 mg/ kg (0.6 g/ sqM)

15

1.5

2-7.5 µg/ mI

++

+

p

20 mg/ kg (1.2 g/ sqM)

25

1.2

IOO-IOOO µg / mI

+++

+

S, P

2-IO mg IV repeated
dose
0.3 mg/ kg

30

IO

I50-550 ng/ mI

6

20

20-70 ng/ mI

500-750 mg/ day
400 mg (children)/ day
1200 mg (adults)/ day
40-80 u

200

I8

I0-75 µg/ ml

23

1.5

4-6 µg/ ml

Indications
DPH
(Dilan tin®)
Phenobarbital
(Luminal®)
Primidone
(Mysoline®)
Ethosuximide
(Zarontin®)
Methsuximide
(Ceiontin®)
Trimethadione
(Tridione®)
Diazepam
(Valium®)
Clonazepam*
Acetazolamide
(Diam ox®)
Carbamazepine*
(Tegretol®)
ACTH

Serum Level•
Therapeutic
Range

S, P, C
P, PMS
L, G
Infantile spasms

ED-Effective dose
C-Complex (myoclonic akinetic, focal and gen., "petit mal variant")
F-Focal seizure
G-Generalized
L-Limbic (Temporal lobe, etc.)
P-Petit mal
PMS-Premenstrual seizures
$-Status epilepticus

++
+++

±

g/ sqM-gram per sq uare body meter
TD-toxic dose
±-Rare
+ -Infrequent
++-Occasional
+++-Not uncommon
*-Use as anticonvulsant experimental
:j:-Gross guidelines

+
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use of phenobarbital or DPH, _in our study of 182
patients suffering from focal as well as generalized seizures (Table 4), patients responded better to phenobarbital or DPH alone than to the
combination of the two drugs. When the patients
were randomly divided into three groups, the group
receiving DPH and phenobarbital in combination
had more tendency to suffer from side effects of
drowsiness and ataxia, and therapeutic levels of the
anticonvulsants could not be achieved in most cases
without the complications of undesired side effects.
The patients who received single anticonvulsants had
a higher level of serum anticonvulsants with fewer
side effects of drowsiness, poor appetite, and
hyperactivity. The patients in the combination group
had more rapid control of seizure disorder from the
start, but did not fare as well in the long-term followup. This was blamed on the fact that the patients on
combination therapy did not follow the treatment
schedule as religiously as the patients in other groups
because of the side effects. The patients receiving individual anticonvulsants had a delay of two-to-five
days in complete control of their seizures, but had
better control of seizure disorder when followed for a
period of over two years (Table 4).
Drug toxicity can be enhanced by the use of hormones such as salt-retaining hormones or by the use
of psychotherapeutic drugs such as phenothiazines. It
is a well-known fact that phenothiazines can exacerbate seizures in some patients; this is especially true in
patients suffering from limbic system originated
seizures. This does not, however, contraindicate the
use of phenothiazines in the epileptic patients. The
use of some phenothiazine drugs may be absolutely
necessary to control the emotional problems which

TABLE 3
Measurement of Blood Levels of Anticonvulsants
I. Patient reliability
2. Undermedication and overmedication
(typical and atypical toxicity; acute and chronic toxicity)
3. Drug interaction
4. Seizure aggravation by anticonvulsants
5. Neurologic deterioration due to drugs vs other causes
6. Use of anticonvulsants in hepatic or nephritic patients

seizure control (4). Notwithstanding this variability
in individual patients, the clinician may become
frustrated with the patient's Jack of response to treatment. Without further inquiry as to the cause of this
Jack of response, the clinician may add subtherapeutic doses of other drug inducers. The combination is apt to fail.
The combination of the following inducers of
drug metabolism should be avoided: 1) phenobarbital
and antipyrine; 2) phenobarbital and butazones; 3)
. phenobarbital and diphenylhydantoin (DPH); 4)
phenobarbital and gyrseofulvin; 5) chlordiazepoxide
and Coumadin®.
Drug interaction is variable from case to case;
however, high anticonvulsant levels are achieved of
each drug, if the metabolic inducers are not given
simultaneously (5). If in some cases a combination of
drugs seems to be more effective, it is most likely that
subtherapeutic doses of each agent have been used to
begin with. This is especially true in combining
phenobarbital and DPH.
The combination of phenobarbital and DPH is
in vogue. While in occasional patients such a combination may be more rewarding than the individual

TABLE 4
Treatment of Focal and Generalized Seizures in 182 Randomly Distributed Patients
Age Range 6-37 Years with a Two-Year Follow-up
No. of
Patients

Mean Blood
DPH (µg / ml)

DPH
5.0 mg/ kg/ day

61

II

Phenobarbital
1.5 mg/ kg/ day

51

Combination

62

6.2

Mean Blood
Phenobarbital (µg/ ml)

Therapeutic Failures
in Two Years
13 (21.3%)

12.3

16 (27.1 %)

7.1

24 (38.6%)

(Reproduced by permission of the American Academy of Pediatrics, Inc., and the author, from H. Hooshmand, "Toxic Effects of Anticonvulsants: General Principles," Pediatrics 53:553, 1974.)
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Fig. IA-Frequent, partial, complex seizures in a three-year-old
boy diagnosed as "petit mal" without success.

may be more incapacitating than the seizures
themselves. Among the phenothiazines, however, the
epileptogenic effect is variable. For example, chlorpromazine (Thorazine®) is a much stronger epileptogenic agent than thioridazine (Mellaril®); the use of
the latter drug is more strongly preferred of the two.
Drug Specificity for the Disease. Whereas in
therapeutic doses, anticonvulsants have in common
the characteristic of raising the threshqld of the
seizure discharge, clinical experience has revealed
that some of the anticonvulsants are more useful for
specific forms of seizures. The review study by
Coatsworth (6) has demonstrated that ethosuximide
is more effective in the treatment of petit mal.
Trimethadione is less effective in petit mal and is not
effective in treatment of generalized convulsive
seizures. Primidone is more helpful in the treatment
of limbic (psychomotor) seizures and is not effective
in petit mal seizures. If these guidelines are used, the
medical treatment will be more successful (Table 2).
22,17~N
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Fig. IB-Methsuximide, 300 mg per day, stopped the seizures.

Fig. 2-Temporal lobe seizures in a 12-year-old boy misdiagnosed
as "petit mal."

It should be kept in mind that an anticonvulsant
may be very effective experimentally for a specific
form of seizure, but it may have a narrow safety
range measured by toxic dose compared to effective
dose (7) (Table 2). The toxic side effects will limit the
usefulness of such an anticonvulsant. This is true for
trimethadione and phenacemide. Phenacemide, an
anticonvulsant tried for treatment of temporal Jobe
seizures, is so toxic that its use is unwarranted (6).
The Nature of the Disease for Which the Drug
is Used. Therapeutic failure may be the result of incorrect diagnosis such as the treatment of hysterical
seizures with anticonvulsants. Other examples may
include treatment of psychosensory seizures
originating from the temporal lobe, misdiagnosed as
petit mal, with medications for petit mal seizure or
treatment of complex infantile seizures as "petit ma!"
seizures (Figs. 1, 2).
Electroencephalography (EEG) can be a
priceless tool in confirming the diagnosis. One cannot
always rely on clinical expertise and judgment in
diagnosis of seizure disorder; EEG must be used as a
guideline for accurate diagnosis and treatment.
Accurate diagnosis of etiologic factors in seizure
disorder is most important in the treatment of
neonatal seizures. More than half of these neonatal
seizures may be caused by correctable factors such as
calcium, magnesium, glucose, or pyridoxine
metabolism disturbance (8). If instead of correcting
these metabolic disturbances, anticonvulsants in
large doses are used, the infant can easily be born
toxic.
The problem of the "breakthrough effect" can
play a significant role in drug toxicity. This problem
refers to the phenomenon of the loss of control of
seizures despite adequate therapeutic blood levels of
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anticonvulsants after a few months or years of
successful !reatment. Some anticonvulsants are more
apt to develop this problem. These include
acetazolamide (Diamox®), nitrazepam (Mogadon®),
and, to a lesser extent, diazepam (Valium®) and
clonazepam (Clonopin®).
In our experience, the breakthrough effect may
also be related to the etiologic factors. In rare cases of
slow-growing gliomas with temporal or frontal lobe
seizures, the breakthrough effect may herald the
presence of the tumor years before the tumor can be
visualized by contrast studies.
The Mode and Frequency of Medication. The
route and the frequency of administration of anticonvulsants plays a role in efficacy and toxicity. The
frequency of administration should be approximately
equal to the half-life of the drug (which is quite
different from one drug to another).
Diphenylhydantoin ( DPH ). The approximate
half-life of DPH in man ranges from 4-50 hours according to various studies. The mean figure is 22
hours. Unfortunately, all patients do not fall in the
mean rate of plasma half-life. As a result, single-dose
administration of DPH can cause fluctuations of the
drug level in the blood in a small number of patients
causing confusion in treatment. This method, which
apparently can be quite effective in adults (9), can
cause some complication in children. In our experience, a single-dose administration of DPH can be
irritative to the stomach, causing nausea and
vomiting. There is no need, however, of dividing the
dosage of DPH to more than two times per day. This
drug should never be given intramuscularly (IM), but
can be administered intravenously or by mouth; IM
use ·causes necrosis of muscle and DPH is not
transferred to the blood from the muscle in any
significant therapeutic dose. DPH should not be mixed
with other IV fluids because it is strongly alkaline.
Long-term administration of over 7 mg/ kg of
DPH causes lethargy, drowsiness, diplopia, confusion, and ataxia; ataxia and nystagmus are crude
signs of toxicity. Rarely, hyperactivity, poor school
performance, psychosis, hallucinations, and delusions may result. Hirsutism, seen in three-fourths
of all patients taking DPH, is annoying but not
serious. Gum hypertrophy is also frequently seen and
can become so severe as to necessitate excision.
Morbilliform rash may occur in 2% of patients;
in these cases, DPH will have to be discontinued.
Even though some patients can later be restarted on
the drug, this is a risky practice. The rare complications of blood dyscrasia and hepatitis definitely

necessitate the permanent discontinuation of all
hydantoins.
A common benign side effect of DPH is
lymphadenopathy. We have seen this to be misdiagnosed as lymphoma or lymphosarcoma. Lupus
erythematosus (LE) is a rare complication which
clears up after the discontinuation of DPH. The family history is positive for LE in one-fifth of these
patients. Another rare complication of DPH therapy
is a mild megaloblastic anemia which can be corrected with 0.1 mg folic acid daily.
Phenobarbital. This anticonvulsant has a half-life
of three-to-six days in man. As a result, a single daily
dose should be efficient and effective. This single dose
is best given at bedtime.
The main side effect of this drug is drowsiness
and/or aggravation of preexisting hyperactivity.
This side effect can be effectively overcome by the addition of methylphenidate (Ritalin®), 10-30 mg in
divided doses in the morning and at noon. A
scarlatiniform rash may develop in 2% of patients.
This necessitates discontinuation of the drug as does
allergic erythematosus rash.
Primidone ( Mysoline®). This drug has a plasma
half-life of 4-19 hours in man with a mean of eight
hours . It should not be given as a single dose, and
preferably should be given every four-to-eight hours;
tolerance to this drug develops slowly.
Diazepam (Valium®). This drug is effective
mainly as an anticonvulsant for the control of status
epilepticus. It should be given in IV form in frequent
doses. The half-life of this drug is not more than three

Fig. 3-Manning (16) depth electrode. (Right) The depth electrode
with six exposure points 5-10 mm apart. (Left) The electrodes seen
in the middle fossa and anterior fossa of the skull. Arrows show
points of exposure.
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TABLE 5
Cases of Intractable Seizures Excluded After Adjustment
of Standard Rx•
6
4

U ndermedication
Drug interaction
Drug toxicity
Wrong diagnosis and Rx:
petit mal vs limbic seizures**
petit mal vs complex seizures***
hyperventilation syndrome
conversion reaction
1 hypoglycemia, 1 lead poisoning
and 1 congenital heart disease

4

5
1

2
3

26

Total

* Of the 70 patients referred for intractable seizure, 26
were satisfactorily treated after correction of diagnosis or
adjustment of medication .
** One case treated successfully with primidone alone,
three cases with carbamazepine.
*** All five responded favorably to methsuximide.

hours. As a result, frequent injections should be given
until the seizure is under control. Diazepam should
not be given IM or by mouth for the treatment of
status epilepticus; neither should it be mixed with
other IV medications; it is most incompatible with
most other IV fluids . This incompatibility manifosts
itself in the form of venous blood coagulation and
pulmonary em bolus, which may have been the major
factor in blaming this drug for the rare complications
of respiratory arrest and death that are due to benzodiazepines.
Clonazepam. This is an effective anticonvulsant
in the treatment of petit mal as well as complex minor
motor seizures ( 10, 11 ). Its half-life is five-to-six hours
and it should be given by mouth every six hours . The
major side effects are drowsiness (when given in toxic
doses) and aggravation of hyperactivity. The
hyperactivity can be corrected by treatment with
methylphenidate (Ritalin®).
Trimethadione. Because of the high tendency for
toxicity in the form of skin rash, blood dyscrasias, as
well as hemeralopia, and because the diones are not
as effective anticonvulsants as succinimides (6), we

TABLE 6
Results of Treatment with Clonazepani in 44 Cases of Uncontrollable Seizures
Type of Seizures
Petit inal (absence)

Photic sensitive
Petit mal status (absencecontinuing)
Sylvian
Myoclonic
Temporal lobe (psychomotor, psychosensory)
Focal cortical

Number of Cases

5

Gen. S & W

Photoconvulsive
Cont. S & W
1

5
7

Follow-up EEG*

EEG

Mid-temporal S
S & W plu s fr o ntal or
temporal S
Temporal S

Results of Rx**

Infrequent or no S & W ;
focal S 2 cases; slow background 3 cases
Normal
Slow background
No S & W
Less frequent S
l'{ o change

++++
+++ 3 cases

Slightly less frequent S

++++ 4 cases

++++ 3 cases
± 2 cases
++++
++++

± 2 cases
± *** 3 cases

4

Focal S (motor 3, Occip. I) No change

++ 3 cases
± 1 caset

A kinetic

Complex (akinetic and
myoclonic)
I nfatitile spasm

10

7

2

S & W, poly S 8:j: plu s
frontal 3 temporal S 2
hemispheric 1
Focal or gen . multiple
· spikes
H ypsarrhythmi a

±
±
No change

S & W-spike and waves
* Low voltage fast activity was invariably present
** 4+ excellent control , - 3+ over 75%, 2+ over 50%, + over 25% decrease of seizures, - no change
*** ± temporary effect
:j: Simultaneous EEG anomalies were common
t Expired (meningitis)

+++ 6 cases
++ 2 cases
± 2 cases
± 6 cases
++ 1 case
- 2 cases
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TABLE 7
Results of Surgical (Ablation) Therapy iii Eight Intractable Seizure Patients
with a Two-to-Eight Year Follow-up
X-Ray
Fingings

Seizure

Age at Ohset
of Seizures

Age at
Surgery

Psychomotor

Neg

8 yrs

14 yrs

Psychomotot

Neg

9 yrs

15 yrs

A kinetic

Neg

11 yrs

17 yrs

Akinetic

Neg

9 yrs

21 yrs

Akihetic &
advetsive
Akinetic &
grand ma!
Complex (akinetic,
focal , gen.)
Grand mal

Neg

2 yrs

6 yts

Neg

12 yrs

22 yrs

Hemiatrophy

Birth

11 yrs

I yr

19 yrs

R. occip.
cyst

Procedure
temporal
lobectomy
temporal
lobectomy
temporal
lobectomy
temporal
lobectomy
frontal lobe
section
frontal lobe
section
Hemispherectomy
Removal of
cyst

Pathology

Seizure Control*
After 2-7 Years

glioma III

++ **

oligodendroglioma
no lesion

+++

gliosis

+ ++ +

AV malformation

++++

gliotic cyst

++++

atrophy

++++

gliosis

±t

+ ++

* 4+ excellent control, - 3+ over 75%, 2+ over 50%, +over 25% decrease of seizures, - No change
** 4 yeats postop, post Ro-Rx, and post chemo-Rx
t Died of E. coli meningitis 13 months postop

have abandoned the use of this drug altogether. The
usual dose in children with petit rnal is 300-900 mg/ day in two-to-three doses.
Succinimides. At present, ethosuximide (Zarontin®) is the drug of choice for petit mal seizures (6). It
can aggravate generalized convulsive episodes in
akinetic and temporal lobe seizure patients {12).
Because of its long half"life, once- or twice-daily
doses should be sufficient. It is metabolized as quickly
in children as in adults.
Methsuximide (Celontin®). In our experience,
~

:!.;"f:

=

14)10.W.M.

this has been a very useful drug in the treatment of
difficult to control (akinetic, myoclonic, etc.) seizures.
One daily dose seems to be sufficient. It has more
tendency for toxic side effects than does ethosuximide
{Table 2). Phenylsuccimide, a bi product of this drug,
has a long half-life and can cause deep coma ( 13).
Carbamazepine ( Tegretol®). Because of fluctuation in blood levels, this drug should be administered
three-to-four times daily. Blood levels of over 7
µg / ml may result in ataxia, nausea, diplopia,
dysarthria, and drowsiness, all dose-related {Table 2).

F,-C.

TABLE 8
Outcome of 70 Cases of Difficult Seizure Control with
Two-to-Eight-Year Follow-up

Ca-pt-........,,.,,N-<"""MNC'-Nr-NNNH"'"""N'-'*-i"i\.i'..f'"'°'"""'""'

Management

and patient IMllllQ

8-2-73
36,698
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.
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,_
Fig. 4-EEG of 14-yeat-old boy suffering from psychosensory
seizures with cortcomitant fluttering of eyes. Note 3/ sec S&W
followed by a left temporal spike transient. Poor response to
·
ethosuximide treatment.

Drug adjustment,
misdiagnosis
Clonazepam
Surgery
Total
Failures-14 cases
(20%)**

Patients

Successful Rx

26
44*
[8]*

23
27
6

70

56

• The surgical cases were from the clon~zepam failure
group.
•• The failure rate was descreased from 100% to 20%.
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TABLE 9
Results of Medical and Surgical Treatment in 32 Patients
Suffering from Akinetic Seizures*
Patients

Intractable

7

5

Complex Akinetic
(age of onset 1-12
yrs, average IQ 82)
and Myoclonic

18

6

Late Onset Akinetic
(age of onset 5-13
yrs, average IQ 89)

7

Lennox syndrome
(age at onset birth5 yrs, average IQ 78)

Total

32

11

* Note the relationship

of patients' age to the prognostic
response to therapy-the later the age of onset of the
disease, the beiter the prognosis.

Rare serious, al\ergic-type complications of blood
dyscrasia, hepatitis, and skin rash may necessitate
discontinuation of this drug (14); however, this drug
can be quite safe and effective in the treatment of
seizure disorders in children ( 15).
Adrenocorticotrophin (ACTH). This is the drug
of choice in infantile spasm. Although it can cause
cushingoid features, this side effect is worth coping
with. Every-other-day dose decreases this side effect.
Management of Intractable Seizures. The following is our experience with the management of intractable seizures.
Material and Method. Seventy intractable partial
seizures were studied and followed for two-to-eight
years. Patients who demonstrated the evidence of
brain tumor or arteriovenous (AV) malformation on
contrast studies were excluded from this study. The
70 patients were evaluated for medical or surgical
treatment. Age range was 2-34 years with an average
of 14 years. The majority of patients were in
childhood and teen-age groups. Thirty-eight were
female, 32 were male.
The depth electrode studies were done on the
patients who had failed to respond to medical treatment, and regardless of the type of generalized EEG
discharges, showed focal spikes in their ictal, interictal, or postictal EEG recordings. Manning (16) depth
electrode was used. This is a fine depth electrode,
thinner than other types, which can be inserted with
little risk of trauma (Fig. 3); its six exposure points,

5-10 mm apart, facilitate recording several points in
depth.
The depth studies were performed immediately
after contrast studies, psychological tests, as well as
an intra-arterial amobarbital test for diagnosis of
cerebral dominance. The ventricular air remaining
from the .air encephalogram was an important guide
in locating the position of the depth electrodes. The
depth electrode studies consisted of the study of the
suspicious focal discharge as well as symmetrical
depth electrodes positioned in temporal lobes, frontal
lobes, and thalamic nuclei. The temporal lobe electrodes were inserted from the posterior temporal
region, advancing towards the amygdaloid nucleus
with the tip of the electrodes resting adjacent to this
nucleus (Fig. 3). This method would provide a recording from surface to depth, from posterior to anterior
aspects of the temporal lobes, and would facilitate
localization of the abnormal discharges. An average
of ten days-to-two weeks of recordings were done and
an attempt was made to record an ictus on depth electrode recording of all patients with the help of allnight EEG n;:cordings or EEG telemetry recordings.
Results. Twenty of the patients were helped by
adjustment of standard medical treatment (Table 5).
Six patients were found to have been misdiagnosed.
This group consisted of one patient with lead poisoning, one with hypoglycemia, and one patient with
congenital heart disease.

I • I an. AV malfcnratioll
(RI mellal frontal

Pre ap. EEG

A 1 -T1 ~

T1-C 1 -'---'~

c,-c~ ~\/''--EV'<•..f'--../._/'-.,'l)''· --(v'"'SurQ«Y- 4-12-72
F'Oot-ap. No Mlzin
Normal EEG.

c.-c. ~
C4 -T4 ~~

~-A,-~
T1-P1 -~

P1-P• ~
P,-P. ~
P4 -T0 ~
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___J!IOJIV
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Fig. 5-Six-year-old girl suffering from intractable seizures. Surface EEG recording shows slow S&W. EEG returned to normal
after removal of a right mesial frontal A Y formation.
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The remaining 44 patients were tried on a benzodiazepine-clonazepam (Table 6). This drug was
most effective in petit ma!, petit ma! status, and
photosensitive seizures. It was less effective in complex seizures and infantile spasm (hypsarrhythmia).
Of the 27 patients who failed to respond to
clonazepam therapy, 15 underwent depth electrode
studies. Of these 15 patients, eight eventually had surgical treatment. These eight patients were selected
after the depth electrode studies revealed that the
epi!eptogenic focus was the source of the patients'
clinical seizures and was amenable to surgical treatment (Table 7).
Despite the fact that repeated angiography and
air encephalography performed in intervals as far
apart as three-to-six years were negative before
operation, with the help of depth electrodes, lesions
such as tumors and AV malformation were found at
the site of epileptogenic focus (Table 7). The end
result was a drop of failure rate from 100% before the
study to 20% at the completion of this study
(Table 8).
Discussion. The clinical and surface EEG
diagnoses are not always accurate. The interictal surface EEG findings do not necessarily correlate with
the region of the epileptogenic focus, and may not be
localizing in even half of the partial, adversive, or
controversive seizures (17, 18). Simultaneous depth
and surface recordings in patients with petit mal
epilepsy reveal inconclusive data regarding the site of
origin of both the spike and slow wave discharges
(19-21).
Experimentally in the monkey, the electrical and
behavioral characteristics of petit mal epilepsy have
been demonstrated by the production of bilateral cortical eplieptogenic foci (22). It has been shown that
the focal cortical paroxysmal discharge has a tendency for subcortical propagation before maturation
and a tendency for cortical propagation after maturation (23). A synchronized EEG discharge is not
necessarily synonymous with subcortical origin. A
cortical focus can give rise to similar seizure
manifestations (29). In occasional cases, the suppression of the generalized 3/ sec spike and wave (S & W)
discharges by medication may help demonstrate the
cortical epileptogenic focus ( 10). The diagnosis of
petit mal does not necessarily point to a subcortical
origin for the generalized discharges, and occasionally, a limbic system focus may mimic the petit mal
attacks (Fig. 4). The limbic system has been
demonstrated to extend to subcortical structures as

well (30). Even in the cases of "typical petit ma!," the
generalized S & W on EEG may be accompanied by
complex behavior and automatism which may be environmentally influenced (31, 32). They may be accompanied by increased or decreased postural tone of
the body (31, 32). The above may explain the complexity of the subject partial seizures and the problem
of misdiagnosis or incorrect treatment.
A large number of patients in this study (Tables
6, 7) suffered from akinetic seizures. This form of
seizure (33-35) may be accompanied by slow S & W
discharges on EEG-the "petit ma! variant" (36, 37).
The akinetic and atonic seizures seem to form a syndrome variable in etiologies as well as in EEG findings. The "Lennox syndrome" (37), a name which
has been used synonymously for these seizures, is
characterized by 1) age of onset, usually below six
years of age; 2) complex seizure manifestations, such
as akinetic and myoclonic seizures; 3) retardation; 4)
resistance to treatment; and 5) generalized slow S & W
discharges plus other abnormalities in three-fourths of
cases (38, 39). Whereas this syndrome comprises the
majority of akinetic seizures in young children who
are also retarded, it does not encompass the entire
spectrum of akinetic seizures.
When the akinetic seizures occur in the older age
patients, or in patients who do not have other aspects
of Lennox syndrome (such as retardation), the
prognosis seems to be more favorable. This is
reflected clearly in our study of 32 akinetic seizure
patients (Table 9). The EEG findings, usually that of
slow S & W discharges in Lennox syndrome, may
demonstrate focal discharges in older age patients
(40-44). Our depth electrode studies confirm cortical
origin of the epileptogenic focus in some of these
patients (Figs. 5, 6; Table 7).
Depth electrode studies may be very helpful in
care of seizure patients if the following minimal
criteria are met: 1) the use of the thinnest possible
depth electrodes; 2) a suggestion offocal discharges on
surface recording; 3) the confirmation of cerebral
dominance by intra-arterial amobarbital test before
any surgical procedure; and 4) the recording of the ictal event from the surgically resectable epileptogenic
focus.
In our experience (Table 7), repeated negative
contrast studies over the years do not rule out the
possibility of brain tutnor or AV malformation as the
cause of seizure disorder (Fig. 5). Crandall (45), in his
experience with depth electrode studies in seven intractable partial seizures, noted one patient suff~ring
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Fig. 6A-Eleven-year-old girl with intractable seizures and leftsided hemiplegia since birth. Surface EEG recording shows
bilateral multispikes.

from corpus callosum astrocytoma who suffered
from attacks of becoming rigid and falling backward
as well as psychomotor seizures. This patient, along
with another patient who had a small meningeal
angioma, had negative contrast studies. Page et al.
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Fig. 6B-Electrocortiography (ECoG) before and after
hemispherectomy. Right-postoperative surface EEG shows no
more spikes. Patient is seizure free. No more need for anticonvulsant therapy.
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UNDER-MEDICATION ; OR WRONG TREATMENT

B

TOXICITY ; OR WRONG DIAGNOSIS

C

SURGICAL TREATMENT; PROGRESSIVE LESIONS

X PARTIAL CONTROL
Fig. ?-Comparison of the results of therapy among seizure
patients referred to the seizure control clinic. As noted, undermedication and overmedication comprise the majority of
failure cases.
(46), while underlining the importance of brain tumor
as the causative factor in rare cases of childhood
seizure disorders, emphasized the fact that a change
of seizure pattern in EEG or in behavioral school performance should make one suspicious of the
possibility of brain tumor as the causative factor.
It is concluded that with adjustment of treatment, accurate diagnostic work-up, trial of new anticonvulsants, and surgical therapy for partial
seizures, the failure rate may drop from 100% to 20%
(Table 8, Fig. 7).
Prevention of Seizure Disorders. The knowledge
about seizure disorders has advanced to the point of
considering prevention.
Prenatal Prevention. Maternal toxoplasmosis,
syphilis, and cytomegalovirus infections should be
diagnosed and aggressively treated. Maternal hygiene
and nutrition play a role in the size of the child. The
low birth-weight children are at risk for neonatal
seizure disorders.
Neonatal and Infantile Prevention. Early
diagnosis and effective treatment of neon atal
meningitis can prevent the late complications of intractable seizures. Immunization, especially for
measles and mumps, should be strongly encouraged.
Febrile seizures should be aggressively treated and
prevented by antipyretic and anticonvulsant
(phenobarbital) therapy to prevent mesial and temporal anoxic damage and subsequent late-onset temporal lobe seizures.
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Prevention of Head Injury. Prevention of head
injury by the use of seat-belts in the car, and by encouraging the schools to avoid building cement floors
under swings in the playground can be helpful.
The Role of Eugenics. The role of eugenics is
limited to such diseases as Huntington's chorea,
phenylketonuria, and mucopolysaccharidosis; however, intermarriage among families with high risk
seizure disorders may be discouraged.
Psychosocial Aspects. This is one area where unfortunately no recent progress has been made. The
general public still has a medieval attitude toward
epileptics. More education for the public as well as
for health officials is needed.

Acknowledgment: I would like to thank Dr.
Donald Becker for the contribution of his surgical
skill which helped make this research work possible.
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Radical Reconstruction of Complex
Cranio-Orbito-Facial Abnormalities*
JOHN A. JANE, M.D., Ph.D. and MILTON T. EDGERTON, M.D.

Departments of Neurosurgery and Plastic Surgery,
University of Virginia, School of Medicine, Charlottesville

Introduction. The two possible justifications for
surgery in craniosynostosis are first, to allow room
for the growing brain, thus preventing damage to
developing neural structures and second, to prevent
or correct deformity. There is considerable doubt
about the extent to which the first consideration is
valid. Objective signs of increased intracranial
pressure are rarely seen with a single closed suture.
This fact, along with the difficulty in demonstrating
either impairment or improvement in psychological
functioning following single suture removal, has led
to a generally negative view toward synostectomy
with a closed single suture. On the other hand, there
is very little question that multiple suture closure can
lead to increased intracranial pressure, and here, early
surgery is certainly justified. This ongoing argument
about the benefits that might accrue with release of
the fused sutures seems to have prevented growth of
interest in the purely cosmetic aspects of the
procedure. Although there is general agreement that
early release gives better long-term results, there has
been very little interest in the late effects of synostosis, such as marked frontal bossing or the associated facial deformities like those seen in Figure I.
We have recently been attempting to reconstruct
complex abnormalities involving the skull, orbit, and
face at a progressively earlier age. Our cases include
such conditions as Apert's and Crouzon's syndromes
and single and multiple premature suture closure. We
wish to present two illustrative cases, one of a com-

bined unilateral coronal and sagittal synostosis and
the other, a Crouzon's syndrome.
Case 1. T. D. was seen at the age of two weeks.
He showed (Figs. I, 2) the typical appearance of a
right unilateral coronal combined with a sagittal synostosis. There was considerable frontal bossing on
the left side opposite the coronal synostosis, which
had resulted in depression of his left orbit. He was

* Presented by Dr. Jane at the 27th Annual Stoneburner Lecture Series, February 7, 1974, at the Medical College of Virginia,
Richmond.

Fig. I-Case I showing flattening of the right brow and depression
of the left orbit in the instance of combined right coronal and sagittal synostosis.
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Fig. 2-View from above showing the extent of the left frontal
bossing resulting in depression of tlie orbit.

Fig. 3-A postoperative view showing improvement in the skull
shape with some residual depression of the orbit.

taken to the operating room where the fused sagittal
suture was removed and used to reconstruct the
deficient orbital rim on the side of the coronal synostosis. A dural graft also was placed on this side,
and the dura was plicated over the side of the frontal

bossing. This resulted in shifting the intracranial contents to the right side with a more normal appearance
of the skull. We consider this maneuver of
remoulding the dura to be an important step in the
long-term results. Figure 3 is a postoperative

Fig. 4A , B-The typical appearance ofCrouzon's deformity with proptosis, underdevelopment of the maxilla, and relative overdevelopment of the mandible.
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Fig. 5-Cadaver skull showing the point at which the osteotomy is
carried out.

Fig. 6-0perative photograph showing the frontal bone being
pulled forward over the orbit.

photograph showing excellent skull shape, although
the orbit is still slightly depressed. facial appearance
has continued to improve.
Case 2. Figure 4A, B shows a 13-year-old girl
with the typical appearance of ~rouzon's disease.
There is relative µnderdevelopment of the maxilla

and overdevelopment of the mandible with proptosis.
Our surgical procedure involved a combined intracranial and extracranial approach; one of the
procedures used is illustrated in Figure 5. The line
across the frontal fossa indicates the cut that is made
in the bone. Figure 6 shows the actual operative

Fig. 7A , B-Postoperative photographs.
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procedure, the frontal bone being moved forward
over the orbits to relieve the proptosis. Figure
7A, B shows the postoperative results.
Discussion. These procedures are generally long
and, particularly when performed on young children, considerable care must be taken in the
mairitenance of blood volume and humidification of
the respiratory system. In the postoperative period,
chronic measurement of intracranial pressure has
also proven to be most helpful.
The first case illustrates what we think may be an
important aspect of the early repair of craniofacial
malformation, that is, the question as to whether
remodeling of the cranial vault alone, without concomitant remodeling of at least the dura, is sufficient
to obtain good late results. It may well be that the underlying brain and dura are the prime factors responsible for the ultimate shape of the cranial vault as has
been suggested {I). Experiments in our own
laboratory also suggest that this is the case. We have
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performed a series of experiments on neonatal hooded rats, in which we have systematically altered the
brain or the dura alone or we have altered both
together. The findings suggest the importance of the
dura and brain in determining skull shape (2).
Summary. Excellent cosmetic results can be obtained by early intervention in severe cranial-orbitalfacial deformity. This intervention should take the
form of a combined intracranial and extracranial approach. While the procedure is of great magnitude,
the benefits to the patient and to the family seem
worth the risk.
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Progress and Problems 1n the
Rehabilitation of Patients with
Central Nervous System Injuries*
L. D. AMICK, M.D.

Professor and Chairman, Department of Physical Medicine and Rehabilitation;
Professor of Neurology, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University, Richmond

The Stoneburner lecturer and other colleagues
have discussed diverse pathologies which may create
a wide spectrum of lesions and dysfunctions of the
central nervous system. Rehabilitation medicine is
primarily involved in the care of patients with
disabilities of skilled motor performance, which
commonly result from neurologic impairment. Additional alterations in performance may be contributed by personality, as well as societal and
cultural backgrounds. Rehabilitation is particularly
opportune when the diseases causing disability are
static, are in prolonged remission, or are only slowly
progressing. Central nervous system dysfunction may
involve sensory, motor, and cognitive performance as
well as psychologic issues. Rehabilitation considered
here is the prevention, minimization, and functional
compensation for neurologic disability. Rehabilitative principals and methods, such as positioning, padding, and range of motjon to avoid decubiti
and contractures, with strengthening exercises,
and with orthotic and prosthetic devices, usually
apply regardless of etiology of the lesions but do
not obviate the need for enlightened individuation of
therapy and the provision of continuing medical
management.
Let us briefly consider the general nature of contemporary rehabilitation with highlights of its

* Presented by Dr. Amick at the 27th Annual Stoneburner
Lecture Series, February 8. 1974, at the Medical College of
Virginia, Richmond.
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progress and problems. Paraplegia and hemiparesis
may be thought of as the models of neurologic
impairment.
Psychologists such as Fink, Maslow, and Benton
have made brilliant contributions to modern
rehabilitation. Their theoretical models of the
processes of human adaptation under stress have
proved important and useful in dealing with the
problems of motivation. A stressful event is a crisis
when the patient's normal coping ability is inadequate for the event. A major neurologic catastrophe
is such a crisis and is a turning point in the life of a
patient (Table I). After the initial neurologic shock in
terms of coma or confusion and atony or areflexia,
the patient's awareness brings initial psychologic
shock marked by anxiety and/ or bewilderment. The
initial stages of recovery and improvement of
neurologic function favor his hope for further gain,
but any considerable persisting disability is usually
rejected by the patient as temporary, since he wishes
and assumes that structure and function will be fully
returned. During this psychologic phase of defensive
retreat and relief of anxiety, possibly even to the
point of euphoria, it not only is not useful for us to
confront the patient with dire facts and probabilities
but is even likely to prove deleterious, this is because
once we, as therapeutic agents, are associated with
anxiety reinforcement, we are less likely to be
accepted later as a constructive guiding force . The
next psychologic phase of admission or acknowledgement of di&ability accompanies the completion of any
MCV QUARTERLY 10(4): 224-228, 1974
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TABLE I
Crisis and Motivation
Time

w

Precipitant

Psychologic Phase

Self-Image

Acute somatic
damage

Shock

Structural threat

Physical recovery

Retreat

"Regain" structure

Early plateau

Admission

Final plateau

Adaptation

Give up structure;
self-depreciation
Form new structure;
renewed self-worth

early improvement and the establishment of an early
plateau of disability. The patient now faces reality
with reactive depression and possibly selfdepreciation or bitterness. During this renewal of
stress, therapeutic support may be critical, and it is
fitting and useful to emphasize the support and
acceptance that the institution and therapists are continuing to provide for the patient. This is based upon
the simple dichotomy of Maslow that people have
basic safety needs pertaining to food, health, security,
and predictable environment, and that these safety
needs are a chassis on which are erected the growth
needs of greater independence, personal achievement,
and creativity. A positive therapeutic environment
takes advantage of the final phase of adaptation, occurring when the patient faces the structure of disability combined with residual capability and
progresses to the struggle for renewed independence,
which will require a different utilization of resources
in his life and reorganization for the future. I should
like to quote a paraplegic physician and
physiatrist, who says, "Management of spinal cord
injury is, today, seriously handicapped by almost exclusive emphasis upon physiologic and pathologic
processes. I believe that greater progress in comprehensive care will be achieved when a true integration is reached in physical and psychosocial therapy. "
Another major concept that has emerged as an
integral part of modern rehabilitation is that of the
comprehensive regional rehabilitation center. Standard-bearers exemplifying this approach are StokeMandeville (England) National Paraplegic Center,
Georgia Warm Springs Foundation, NYU-Bellevue
Institute of Physical Medicine and Rehabilitation,
and Rancho Los Amigos, California. This concept is
further being supported and tested by the federal
government in the recent proliferation of spinal cord

Affect and Cognition
Overwhelming anxiety;
cannot plan, understand
Avoids reality; a utistic; resists
change
Faces imposing reality;
depressed ± bitter
New reality, satisfactions;
reorganizes resources, future

tnJury centers in this country adding to the preexistent ones in a few VA hospitals. Much significant
research and development have emanated from these
centers. Virginia is privileged to have three such
centers, some of whose contributions will be mentioned, at the McGuire VA Hospital in Richmond, at
the Tower Hospital for traumatic paraplegics in
Charlottesville, and at the the Woodrow Wilson
Rehabilitation Center in Fishersville. A medical
school has regional and exemplary functions and
should itself, through a department of rehabilitation
medicine or through its affiliates, develop a comprehensive rehabilitation center. We have embarked
on this course at the Medical College of Virginia.
Another major concept has been evolving at the
direct therapeutic level-the concept of organ reserve
applied to the brain, sometimes called cerebral
plasticity, which contends that surviving cerebral
parenchyma may be trained to perform the functions
of destroyed tissue. This phenomenon must be distinguished from restored function in temporarily
malfunctioning but intact tissue. A good example is
found in disability caused by cortical sensory defects.
We are familiar with the loss of recognition of objects
being handled, a loss of stereognosis, due to a parietal
lobe lesion. Ruch and Fulton earlier demonstrated in
primates that when one of three principal regions of
sensory cortex is ablated there is a marked decrease in
stereognosis but, with further training, this function
will return . Forster and Shields pointed out the
implication that we may retrain patients to recover
stereognostic function . Instances of improvement
following such retraining in occupational therapy occur, although there are obvious limits to this process.
Closely related to this concept are the various
methodic approaches to the physical therapy of
voluntary motor dysfunction based upon propriocep-
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tive or reflex facilitation. Cohen's experimental
results showed that while the effect of such facilitation of the limbs upon cortically induced muscle contractions could be generalized for the whole population, the influence, whether facilitatory or inhibitory,
of a given sensory stimulus in a single individual
remained consistent under repetitive testing. We are
appropriately skeptical of specific "method schools"
of therapy, but we welcome the safe, empirical trial of
various techniques in some individual patients.
The concept of operant conditioning explored by
Skinner and Bachrach is currently in vogue and is
being vigorously tested in a number of rehabilitation
centers; it essentially supports a learning theory that a
voluntary choice or act on the part of patient may be
rewarded so that he will choose to repeat the act and
thus may eventually perfect it-positive reinforcement of behavior and means of motivation. Benton,
Blackburn, and Shankweiler specifically studied
motivational influences on performance in braindamaged patients and controls. Standard retest instructions brought little change but both "urging" instructions and "failure" instructions that told the
patient he was not doing well resulted in significant
improvements in performance in both groups. There
was no breakdown in performance in the face of this
degree of stress. By contrast, both instructions to
"relax" and "success" instructions telling the patient
he was doing very well brought only small or no improvement in performance. They conclude that a
complete concept of motivation includes readiness to
engage in specific modes of behavior as well as a drive
level of sufficient strength to energize that behavior.
This internal state of the organism consisting of drive
level and behavior-readiness is decisive in determining the possibility and rate of modification of
behavior in learning situations.
Let us descend for a moment from the brain to
the bladder. Spinal cord injury often disturbs bladder
function, and ever after we must also continue to
share with the patient a concern for preservation of
the upper urinary tract. Urostasis and insertion of
catheters lead to urinary infection which readily
ascends. Another renal threat is back pressure from
obstruction or vesicoureteral reflux. Cord injury
above the conus gives a spastic bladder, called
automatic or reflex, that may empty in a sporadic,
unpredictable manner either without a catheter or
around a catheter. If residual urine is modest, this
reflex bladder is satisfactory, particularly in men who
learn to use an external collecting appliance. Diffi-

culty arises when spasticity spreads to the external
urethral sphincter and blocks urinary outflow. When
detrusor pressure dominates over the sphincter, we
have a so-called "balanced bladder," whereby we
may say that the spasticity which creates a reflex
bladder is good. But spasticity which is severe or excessive is apt to involve the sphincter and be unfavorable. In fact, we have learned that decubitus,
calculus, infection, and indwelling catheters are potent stimuli to cord facilitation which can lead to excess spasticity and obstruction to urinary outflow.
Abramson even contends that the nature of the
spasticity after cord injury "seems to be perma nently
influenced by the consistency with which noxious
stimuli arrive at the cord during its (posttraumatic)
functional reorganization." The special importance
of preventing these early complications becomes obvious. Guttmann at Stoke-Mandeville proved that intermittent catheterization from the beginning, never
resorting to the indwelling catheter, will keep the
urine sterile and so allow greater residual toleration
without risk of ascending infection. This has been
verified in this country in hospitals where the required but expensive personnel utilization has been
funded. Nevertheless, imbalance between detrusor
and sphincter tone may occur. Bunts and Hackler
at McGuire VA Hospital followed Gibbons' lead to
develop the external sphincterotomy to decrease
urethral resistance and thus to restore balance. This
succeeded in restoring a negligible postvoiding
residual urine in 74% of 150 patients, the majority of
whom have maintained this good result beyond five
years. Given a permanent neurologic defect, the wish
to eliminate use of the indwelling catheter, residual
urine more than 30 percent of bladder capacity,
and a pos1t1ve sphincterometrogram, Bunts
and Hackler favor such surgery without further
delay. They have found pudenda) neurectomy to be
less effective. Regular six-month reevaluations, including cystourethrogram, appear advisable for all
paraplegic bladders. If reflux or a small spastic
bladder develops, Bunts and Hackler then advise a
selective rhizotomy to convert the spastic reflex
bladder to a lower motor neuron or flaccid bladder.
The latter may be emptied by abdominal contraction
or Crede maneuver. They consider surgeries at the
ureteral level such as ileal conduit only as a later
resort.
Several other research developments are also
worth mentioning. Kantowitz implanted a radiolinked bladder stimulator in three male paraplegic
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patients with variable results-the electrodes might
corrode and might lose their position in the bladder
wall, and an effective voltage might close the external
sphincter. Grimes (Fig. 1). Nashold, and Currie at
Duke University reported last year that they have
implanted electronic stimulators (neuroprostheses)
directly into the sacral spinal cord itself in five
paraplegic patients. One patient had a temporary
tendency to autonomic hyperreflexia and male
patients obtained penile erection from such stimulation and three patients have maintained good
bladders by this means for more than a year. Others
have even proposed to restore a functional gait in
paraplegic man by programming the electronic
stimulation of peripheral nerves in series, intending
to produce muscle contractions in a pattern of ambulation. Nooney at MCV has developed a tiny mirror attachment for spectacles to permit awareness
of the blind side in homonymous hemianopia. Robinson and Warner at the Yerkes Regional Primate
Research Center have evoked certain behavior patterns in monkeys using remote control telestimulation (Fig. 2). In a more extensive study (of electrically controlled behavior in animals, von Holst and
von Saint Paul at the Max Plank Institute for the
Physiology of Behavior in Seewiesen, Germany, were
able with brain electrodes to make the chicken carry
out most of the actions of its normal repertory and
thus clarify the nature of its drives (Fig. 3). In the upper and lower photograph at the left, a formerly in-

Fig. I-Implantable stimulator and electrode assembly with portable transmitter.

227

Fig. 2-Mounting evoked by telestimulation of the lateral
hypothalamus.

different rooster was electrically stimulated to attack
a small stuffed predator, culminating in attack with
spurs and triumphant call. At the right, the same
rooster which had always treated the keeper as a
friend is shown attacking the keeper's face which
appears to be a better substitute for an enemy than
her hand. If all substitutes for an enemy are lacking,
the rooster exhibits only motor restlessness. They
concluded from duplicating various natural drives
that stimulation of the brain stem set off essentially
complete and normal processes and that effects of
stimulation are therefore not imitations or "pseudoaffective" states but genuine drives. " The organism comprises a bundle of drives which support
one another or oppose one another to greater or
lesser extent. Spontaneous activity is the result of a
continual and shifting interplay in forces of the central nervous system." Freedman et al report that electrical stimulation of the septal brain area in humans
has halted epileptic seizures, dulled the pain of
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cancer, produced sexual pleasure, and brought relief
from anger and frustration.
It is difficult to predict what ethical dilemmas
future technological developments may bring, but in
the sweep of progress, we expect that CNS function
will be spared and restored as a result of further
breakthroughs in biologic and behavioral research.
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how big a dose will now
bring relief ii it is a narcotic?
"Tolerance is an ever-present hazard to continued use
of narcotics.... The very first dose diminishes the
effects of subsequent doses."! And, as increasing
amounts of narcotics are required to control pain, distressing adverse effects-lethargy, hypotension, constipation, etc.- can needlessly debilitate the patient.
1. Sadove, M. S.: A look at narcotic and non-narcotic analgesics,
Postgrad. Med. 49:102, June 1971.

how big a dose will now
bring relief ii it is Talwin®?
Chances are, the same 50 mg. Talwin Tablet you prescribe originally will continue to provide good pain
relief. Talwin can be compared to codeine in analgesic
efficacy: one 50 mg. tablet appears equivalent in analgesic effect to 60 mg. (1 gr.) of codeine. However,
patients receiving Talwin Tablets for prolonged periods
face fewer of the consequences you've come to expect
with narcotics. There should be fewer "adverse effects"
on her way of life.
Tolerance rare: Tolerance to the analgesic effect of Talwin
Tablets is rare.
Dependence rare: During three years of wide clinical use,
there have been a few reports of dependence and of withdrawal symptoms with orally administered Ta/win. Patients
with a history of drug dependence should be under close
supervision while receiving Ta/win orally.
In prescribing Ta/win for chronic use, the physician should
take precautions to avoid increases in dose by the patient
and to prevent the use of the drug in anticipation of pain
rather than for the relief of pain.*
Generally well tolerated by most patients*: Infrequently
causes decrease in blood pressure or tachycardia; rarely
causes respiratory depression or urinary retention; seldom
causes diarrhea or constipation. Acute, transient CNS effects,
described in product information, have occurred in rare
instances following the use of Talwin Tablets. If dizziness,
lightheadedness, nausea, or vomiting is encountered, these
effects may decrease or disappear after the first few doses.
*See important product information for adverse reactions, patient
selection, prescribing and precautionary recommendations.

in chronic pain
of moderate to severe intensity

Talw'in®::i.

Talwin® Tablets brand of pentazocine (as hydrochloride)
Analgesic for Oral Use Indication: For the relief of moderate to severe pain.
Contraindication: Talwin should not be administered to patients who are
hypersensitive to it.
Warnings: Drug Dependence. There have been instances of psychological
and physical dependence on parenteral Ta/win in patients with a history of
drug abuse and, rarefy, in patients without such a history. Abrupt discon·
tinuance to/lowing the extended use of parenteral Ta/win has resulted in
withdrawal symptoms. There have been a few reports of dependence and of
withdrawal symptoms with orally administered Ta/win. Patients with a history of drug dependence should be under close supervision while receiving
Ta/win orally.
In prescribing Ta/win tor chronic use, the physician should take precautions
to avoid ingeases in dose by the patient and to prevent the use of the drug
in anticipation of pain rather than for the relief of pain.
Head tn1ury and Increased /ntracraniat Pressure. The respiratory depressant
effects of Talwin and its potential for elevating cerebrospinal fluid pressure
may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a preexisting increase in intracranial pressure. Furthermore, Talwin can produce effects which may obscure the clinical course of
patients with head injuries. In such patients, Talwin must be used with extreme caution and only if its use is deemed essential.
Usage in Pregnancy. Safe use of Talwin durini: pregnancy (other than labor)
has not been established. Animal reproduction studies have not demonstrated teratogenic or embryotoxic effects. However, Talwin should be
administered to pregnant patients (other than labor) only when, in the judgment of the physician, the potential benefits outweigh the possible hazards.
Patients receiving Talwin during labor have experienced no adverse effects
other than those that occur with commonly used analgesics. Talwin should
be used with caution in women delivering premature infants.
Acute CNS Manifestations. Patients receiving therapeutic doses of Talwin
have experienced, in rare instances, hallucinations (usually visual), disorientation, and confusion which have cleared spontaneously within a
period of hours. The mechanism of this reaction is not known. Such patients
should be very closely observed and vital signs checked. If the drug is reinstituted it should be done with caution since the acute CNS manifestations may recur.
Usage in Children. Because clinical experience in chi ldren under 12 years of
age 1s limited, administration of Talwin in this age group is not recommended .
Ambulatory Patients. Since sedation, dizziness, and occasional euphoria
have been noted, ambulatory patients should be warned not to operate
machinery, drive cars, or unnecessarily expose themselves to hazards.
Precautions: Certain Respiratory Conditions. Although respiratory depression has rarely been reported after oral administration of Talwin, the drug
should be administered with caution to patients with respiratory depression
from any cause, severely limited respiratory reserve, severe bronchial
asthma and other obstructive respiratory conditions, or cyanosis.
Impaired Renal or Hepatic Function . Decreased metabolism of the drug by
the liver in extensive liver disease may predispose to accentuation of side
effects. Although laboratory tests have not indicated that Talwin causes or
increases renal or hepatic impairment, the drug should be administered
with caution to patients with such impairment.
Myocardial Infarction . As with all drugs, Talwin should be used with caution
in patients with myocardial infarction who have nausea or vomiting.
Biliary Surgery. Until further experience is gained with the effects of Talwin
on the sphincter of Oddi, the drug should be used with caution in patients
about to undergo surgery of the biliary tract.
Patients Receiving Narcotics . Talwin is a mild narcotic antagonist. Some
patients previously given narcotics, including methadone for the daily treatment of narcotic dependence, have experienced withdrawal symptoms after
receiving Talwin.
CNS Effect. Caution should be used when Talwin is administered to patients prone to seizures; seizures have occurred in a few such patients in
association with the use of Talwin although no cause and effect relationship
has been established.
Adverse Reactions: Reactions reported after oral administration of Talwin
include gastrointestinal: nausea, vomiting; infrequently constipation; and
rarely abdominal distress, anorexia, diarrhea. CNS effects: dizziness, lightheadedness, sedation, euphoria, headache; infrequently weakness, disturbed dreams, insomnia, syncope, visual blurring and focusing difficulty,
hallucinations (see Acute CNS Manifestations under WARNINGS); and rarely
tremor, irritability, excitement, tinnitus. Autonomic: sweating; infrequently
flushing; and rarely chills. Allergic: infrequently rash; and rarely urticaria,
edema of the face. Cardiovascular: infrequently decrease in blood pressure,
tachycardia . Hematologic: rarely depression of white blood cells (especially
granulocytes), usually reversible and usually associated with diseases or
other drugs which are known to cause such changes, moderate transient
eosinophiloa. Other: rarely respiratory depression, urinary retention, toxic
epidermal necrolysis.
Dosage and Administration: Adults. The usual initial adult dose is 1 tablet
(50 mg.) every three or four hours. This may be increased to 2 tablets (100
mg.) when needed. Total daily dosage should not exceed 600 mg.
When antiinflammatory or antipyretic effects are desired in addition to
analgesia, aspirin can be administered concomitantly with Talwin.
Children Under 12 Years of Age. Since clinical experience in children ynder
12 years of age is limited, administration of Talwin in this age group 1s not

oeJr~7)~eg?'j.i·erapy.

Patients with chronic pain who have received Talwin
orally for prolonged periods have not experienced withdrawal symptoms
even when administration was abruptly discontinued (see WARNINGS). No
tolerance to the analgesic effect has been observed. Laboratory tests of
blood and urine and of liver and kidney function have revealed no significant abnormalities after prolonged administration of Talwln.
Overdosage: Manifestations. Clinical experience with Talwin overdosage has
been insufficient to define the signs of this condition.
Treatment. Oxygen, intravenous fluids, vasopressors, and other supportive
measures should be employed as indicated. Assisted or controlled ventilation should also be considered. Although nalorph ine and levallorphan are
not effective antidotes for respiratory depression due to overdosage or unusual sensitivity to Talwin, parenteral naloxone (Narcan®, available through
Endo Laboratories) is a specific and effective antagonist.
Talwin is not subject to narcotic controls.
How Supplied: Tablets, peach color, scored. Each tablet contains Talwin
(brand of pentazocine) as hydrochloride equivalent to 50 mg. base. Bottles
of 100.
(1623 A.)
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A service to medical education from A. H . Robins:
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S erles
on physical examination
of the abdomen:
Normally palpable organs:
the edge of the liver descending,
on inspiration , below the costal
margin (A}; the lower pole of the
right kidney (B}; the abdominal
aorta CC}; the descending colon
and the sigmoid (D}; the ascending colon (E}; and occasionally
the bladder (though rising of
this organ beyond the pubis
does not necessarily indicate
disease}.
Impossible to outline, unless
diseased, distended or enlarged:
the gallbladder, pancreas,
stomach, small intestine, transverse colon and spleen.
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The A . H. Robins G I Series consists of six booklets, designed to provide a quick. yet comprehensive review of basic procedures and practices in
G .I. medicine - with particular emphasis on the
physical examination as performed in lhe office or
'
at bedside If you have teaching respons1bilit1es.
limited quantities are available: Part 1 - /nspec110n.
Part 2 - Palpation . Part 3 - Percuss;on. Part 4 - Auscullaf/on. Part 5 Abdominaf Pain and Part 6 - 0ifferent1af 01agnos1s of Abdominal
Disorders. Write to: The Medical Department . A H . Robins Company,
1407 Cummings Drive. Richmond . Virginia 23220

A service to medical education from A. H. Robins:

Excerpted from Volume 2
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on physical examination
of the abdomen:

The A H Robins G I Series consists of six booklets. designed to provide a quick. yet comprehensive review of basic procedures and practices 1n
G I m edicine-with particular emphasis on the
physical exam1nat1on as performed in the office or
a t bedside If you h ave teaching respons1bl11t1es.
l1m1ted Quant1lles are available: Part 1 lnspeclion .
Pa rt 2-Palpalion. Part 3 - Percuss,on. Part 4 - Auscultation. Part 5Abdominal Pain and Part 6 - 0ifferent1al Diagnosis of Abdominal
Disorders Write to: The Medical Department. A H Robins Company.
t407 C umming s Drive. Richmond . Virginia 23220

Normally palpable organs:
the edge of the liver descending,
on inspiration, below the costal
margin (A); the lower pole of the
right kidney (BJ; the abdominal
aorta (CJ: the descending colon
and the sigmoid (DJ; the ascending colon (El: and occasionally
the bladder (though rising of
this organ beyond the pubis
does not necessarily indicate
disease).
Impossible to outline, unless
diseased, distended or enlarged:
the gallbladder, pancreas.
stomac h, small intestine, transverse colon and spleen.

each tablet.
capsule or 5 cc.
teaspoonful
of elixir
(23%alcohol)

each
Don natal
No. 2

each
Extentab

hyescyamine sulfate
0.1037mg.
0. 1037 mg.
0.311 1 mg.
atropine sulfate
0.0194 mg.
0.0194 mg.
0.0582mg.
hyosc1ne hydrobromide
0.0065 mg.
00065mg.
0.0195mg.
Phenobarbital
(V.. gr.) 16.2 mg (Y.? gr.) 32.4 mg. (%gr.) 48.6 mg.
(warning may be habit forming)

•

Brief summary. Adverse Reactions: Blurring of vision , dry mouth.
d1ff1cult urination, and flushing or dryness of the skin may occur
on higher dosage levels, rarely on usual dosage. Contraindications: Glaucoma; renal or hepatic disease; obstructive uropathy
(for example, bladder .n.eck obstruction due to prostatic hypertrophy); or hypersens1t1v1ty to any of the ingredients.

A·H·ROBINS

AH Rob1nsCompany. R1chmond. Virgin1a23220

•
each tablet.
capsule or 5 cc.
teaspoonful
each
of elixir
Don natal
No. 2
(23% alcohol)
0 . 1 037 mg .
hyoscyamine sulfate
0. 1037mg.
0.0194 mg .
atropine sulfate
0.0194 mg .
0.0065 mg.
hyoscine hydrobromide
00065mg.
(JI.I gr.) 16.2 mg (1-2 gr.) 32.4 mg.
Phenobarbital
(warning may be habit forming)

each
Ex ten tab
0.3111 mg .
0.0582mg .
0.0195mg.
(o/. gr.) 48.6 mg.

•

Brief summary. Adverse Reactions: Blurring of vision, dry mouth,
difficult urination, and flushing or dryness of the skin may occur
on higher dosage levels, rarely on usual dosage. Contraindications: Glaucoma; renal or hepatic disease; obstructive uropathy
(for example, bladder neck obstruction due to prostatic hypertrophy}: or hypersensitivity to any of the ingredients.

A·H·ROBI NS

A H Robins Company. Richmond. V1rg1nia 23220

Before prescribing, please consult
complete product information, a summary of which follows:
Indications: Tension and anxiety

states, somatic complaints which are
concomitants of emotional factors; psychoneurotic states manifested by tension,
anxiety, apprehension, fatigue, depressive symptoms or agitation; symptomatic
agitation. tremor.
relief of acute
tremens
and hallucinosis
due to delirium
acute
alcohol withdrawal; adjunctively in skeletal muscle spasm due to reflex spasm to
local pathology, spasticity caused by
upper motor neuron disorders, athetosis,
stiff-man syndrome, convulsive disorders
(not for sole therapy).
Known
hypersensitivity contraindicated:
to the drug. Children
under
6
months of age. Acute narrow angle glaucoma; may be used in patients with open
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patients. Caution against hazardous
occupations requiring complete mental
~
alertness. When used adjunctively in convulsive disorders, possibility of increase
in frequency and/ or severity of grand mal
l ... !, . _
\"~ .
seizures may require increased dosage of
\_ ,.
_
I
standard anticonvulsant medication;
~~~~~ ~-- ~
·
,
abrupt withdrawal may be associated
~
~
~
7
with temporary increase in frequency
~ •~~.
.~
\~ ~
and/ or severity of seizures. Advise
~ _
against simultaneous ingestion of alcohol
and other CNS depressants. Withdrawal
symptoms (similar to those with barbitu\
rates and alcohol) have occurred following abrupt discontinuance (convulsions,
tremor, abdominal and muscle cramps,
vomiting and sweating). Keep addictionprone individuals under careful surveil- - .
lance because of their predisposition to
habituation and dependence. In pregnancy, lactation or women of childbearing
age, weigh potential benefit against
possible hazard.
Precautions: If combined with other
psychotropics or anticonvulsants, consider carefully pharmacology of agents
employed; drugs such as phenothiazines,
narcotics, barbiturates, MAO inhibitors
and other antidepressants may potentiate
its action. Usual precautions indicated in
patients severely depressed, or with latent
depression, or with suicidal tendencies.
Observe usual precautions in impaired
renal or hepatic function. Limit dosage to
smallest effective amount in elderly and
debilitated to preclude ataxia or oversedation.
Side Effects: Drowsiness, confusion,
diplopia, hypotension, changes in libido,
nausea, fatigue, depression, dysarthria,
jaundice, skin rash, ataxia, constipation,
headache, incontinence, changes in salivation, slurred speech, tremor, vertigo;
urinary retention, blurred vision . Paradoxical reactions such as acute hyperexcited states, anxiety, hallucinations,
increased muscle spasticity, insomnia,
rage, sleep disturbances, stimulation
have been reported; should these occur,
discontinue drug. Isolated reports of neutropenia, jaundice; periodic blood counts
and liver function tests advisable during
long-term therapy.
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When, for example, despite counseling,
tension and anxiety continue to produce
distressing somatic symptoms

. Promnt action
is a gooCI reason to
considerValium

®

Roche Laboratories

Division of Hoffmann-La Roche Inc.
Nutley, N.J. 07110

(diazepam)

2-mg, 5-mg, 10-mg tablets

